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ABSTRACT
INVESTIGATION INTO SELECT ISOQUINOLINES
AS A PUTATIVE CAUSAL AGENT OF ETHANOL ADDICTION IN MAMMALS
by Jacob Christopher Strawbridge
May 2009

Alcohol is the most abused drug in America today. The neurological root of the
problem is still a much debated subject and many differing views exist on the nature of
alcoholism, be it a social dysfunction or a neurochemical imbalance. Some researchers
have proposed that a skewed metabolism of dopamine that results in the formation of
tetrahydroisoquinoline (THIQ) alkaloids plays a major role in the neurochemical
acquisition and maintenance of alcohol addiction. In an effort to better understand the
relationship of THIQ's to alcohol addiction, a series of experiments have been conducted.
The chiral separation via high pressure liquid chromatography (HPLC) of various
salsolinol (SAL) and salsolinol-derived compounds using a macrocyclic substituted
sugar, sulfated P-cyclodextrin, as a chiral mobile phase additive was investigated. These
HPLC separations yield data on a cheap and effective method for resolving enantiomers
of simple catecholamines. The second set of experiments involved measuring the ethanol
intake of rats given intracerebro ventricular (ICV) injections of racemic
tetrahydropapaveroline (THP) and R-(+)-THP. A similar experiment was conducted with
tetrahydroberbine (THB). Finally, rats were administered ethanol solutions via gavage

u

and the local cerebrospinal fluid (CSF) in the lateral ventricle of the rats' brains was
sampled via microdialysis. These dialysate solutions were assayed for THP concentration
using high pressure liquid chromatography with electrochemical detection (HPLC-ECD).
The results of our experiments indicate that THP is formed in vivo in the rat brain and
THP levels increase in response to ethanol ingestion. This finding appears to support the
hypothesis that THP plays an important role in the etiology or symptoms of alcoholism in
humans.
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CHAPTER I
INTRODUCTION AND BACKGROUND
Ethanol and Alcoholism
Throughout history, ethanol has played an important part in human society. It
has inspired uncounted artists, musicians, and poets. However, one cannot speak of
ethanol without coming to grips with alcoholism. Alcoholism has been defined by
Koob, a prominent addiction researcher, as a complex behavioral disorder
characterized by excessive consumption of ethanol, the development of tolerance and
dependence, and impairment in social and occupational functioning [1]. Alcoholism
is a serious health concern in America, as alcohol is the most widely used
psychoactive drug [2] and is the third leading cause of preventable death in America
[3]. A relative comparison of the alcohol-related healthcare costs versus the
corresponding health care costs for all other drugs of abuse can be seen in Figure 1
[4]-
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Figure 1: Comparison of Estimates From the Major Cost-of-Illness Studies for
Alcohol and Drug Abuse, Adjusted for Inflation and Population Growth [4]

In January 1987, the National Institute of Alcohol Abuse and Alcoholism
(NIAAA) stated that two-thirds of the American population drank ethanol. However, ten
percent of those who drank accounted for one half of all the alcohol consumed [5]. In
1994, it was estimated that nearly eight million Americans were alcoholics [6]. Clearly,
the etiology of alcoholism merits further study.
A better understanding of the phenomena associated with craving of ethanol and
the reward mechanisms involved could lead to more efficient treatments for alcoholics.
Due to the complexity of alcohol addiction in humans, a problem that has psychological,
genetic, sociological, and ethical components, researchers rely on the use of animal

models, genetic profiling of family histories, and anecdotal accounts to assess the
neurochemistry of ethanol addiction.
The metabolism of ethanol in the liver and brain of mammals is well established
[7, 8]. As shown in Figure 2, ethanol is converted to acetaldehyde by alcohol
dehydrogenase found in cytosol, the liquid component of the cytoplasm, and the cofactor
nicotinamide adenine dinucleotide (NAD+). Acetaldehyde is then oxidized by an NAD+ dependent aldehyde dehydrogenase found in mitochondria and NAD+ to form the acetate
ion. This acetate product is then eliminated from the body.

CH3CHtOH

Ethanol

Alcohol dehydrogenase
(Cytosol)
OHl^C - H
II

Acetaldehyde

Acetaldehyde
dehydrogenase
(Mitochondria)
CH3C - O"
li
Acetate
0

Figure 2: The Metabolism of Ethanol
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Ethanol exerts its intoxicating effects on the central nervous system (CNS) by
shifting the normal processes of information conduction and transmission in an indirect
manner. A nerve cell must maintain a certain concentration of K+, CI", and Na+ in the
extracellular fluid in order to generate action potentials and allow Ca+2 to release
neurotransmitters. When an action potential reaches the terminus of the axon,

ions

enter the presynaptic terminal through voltage-gated ion channels specific for Ca+2 and
signal the release of the stored dopamine into the synaptic cleft.
Insights into the mechanisms by which ethanol affects CNS activity have been
derived primarily from neurochemical assessments of ethanol's actions. Ethanol is known
to inhibit sodium and potassium ion channels in the brain [9-12]. Ethanol has also been
shown to increase calcium ion binding in the brains of rats and mice [13], resulting in a
decrease in free calcium ions in select brain areas [14].
While these discoveries may help explain the effects of ethanol on nerve signal
conductance, the complexity of the neural environment of even experimental animals has
produced a controversy in the neuroscience community over the exact mechanism by
which ethanol dependence operates. The current controversy revolves around the causal
agents of dependence and whether changes in the dopaminergic, the endogenous opioid
systems, or other circuits play the most important role in the etiology of alcoholism.
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Dopamine as a Neurotransmitter
Dopamine (DA) is one of the major neurotransmitters in the CNS. Figure 3 shows
five of the prominent neurotransmitters. Dopamine, also called hydroxytyramine, is a
monoamine intermediate formed from dihydroxyphenylalanine (DOPA) during the
metabolism of the amino acid tyrosine [15]. Figure 4 demonstrates the synthesis of
dopamine in the CNS.

Figure 3: Five Major Simple Neurotransmitters
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Figure 4: Dopamine Synthesis In Vivo From Tyrosine

Dopamine is commonplace in the medial forebrain bundle and important in the
substantia nigra, basal ganglia, and corpus striatum of the brain [16-19]. Figure 5 shows a
variety of dopamine pathways located in the human brain. Dopamine can be both
excitatory and inhibitory, depending on the postsynaptic receptor. It has been implicated
in several functions, including locomotion, learning, attention, temperature regulation
[15], and as a reinforcing agent for drugs of abuse via the nucleus accumbens and the
mesolimbic reward pathway [1, 20-27].

frontal lobe

basal ganglia

Figure 5: An Overview of Dopamine Pathways in the Human Brain

Dopamine, once synthesized, is stored in vesicles in the presynaptic neuron's
terminal button. Ca ions enter the presynaptic axon and signal the release of dopamine
into the synaptic cleft. This released dopamine then binds with postsynaptic receptors and
generates a signal, either excitatory or inhibitory, in the postsynaptic neuron. This process
is then repeated in the next series of dopaminergic neurons. A schematic of a normal
dopaminergic synapse appears as Figure 6.
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Figure 6: A Diagram of a Dopaminergic Synapse

The metabolism of dopamine is, in part, a simple oxidation. Dopamine is oxidized
by monoamine oxidase (MAO) to 3,4-dihydroxyphenylacetaldehyde (dopaldehyde).
Dopaldehyde is oxidized by aldehyde dehydrogenase to form 3,4-dihydroxyphenylacetic
acid (DOPAC). Figure 7 shows the known dopamine metabolism in mammals [28-31].

COOH

dopamine

dopaldehyde

DOPAC

Figure 7: Dopamine Metabolism

Catecholamine Theory of Alcohol Addiction
Two slightly different mechanisms for the development of alcoholism were
suggested independently by separate groups some thirty years ago. The first involved the
formation of tetrahydroisoquinoline (THIQ) alkaloids from the condensation of dopamine
or DOPA with acetaldehyde, the first metabolite of ethanol [32]. This condensation
reaction produced a 1-methyl-THIQ, salsolinol (SAL), and its carboxylated derivatives,
the D and L isomers of 3-carboxysalsolinol (D-3-CSAL and L-3-CSAL). Another
condensation of dopamine with pyruvic acid produces the 1-carboxysalsolinol (1-CSAL)
derivative of SAL. Figure 8 shows the relevant reactions involved in these condensations.
This theory was supported by the discovery that SAL could be formed in vitro by
perfusing bovine adrenal gland homogenates with acetaldehyde solutions [32]. Further
studies confirmed that SAL was formed in vivo in rat [33, 34] and in man [35, 36]. More
recently, it was shown that the condensation of dopamine and acetaldehyde to form SAL
is enzymatically driven, hence forming a majority of the R-(+)-isomer of SAL [37, 38].
Other studies have shown that intracerebroventricular (ICV) perfusion of SAL can elicit a
drinking response from alcohol avoiding animals [39, 40]. Recently, SAL has been the
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object of study because of the neurotoxicity of one of its metabolites that may be a
contributing factor in the development of Parkinson's disease [41-43].
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Figure 8: The Formation of SAL and CSAL

Another group of researchers [31] proposed the second major catecholamine
theory of alcoholism at virtually the same time. This theory held that the presence of
acetaldehyde could inhibit the conversion of dopaldehyde to DOPAC, as acetaldehyde
has a high affinity for aldehyde dehydrogenase also [31]. Alcohol, by way of its primary
metabolite acetaldehyde, facilitates the formation of tetrahydropapaveroline (THP) by
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competitively inhibiting aldehyde dehydrogenase in vitro. Under circumstances of
substantial alcohol ingestion in vivo, the limited ability of the brain to oxidize aldehydes
could contribute to the formation of THP [28-31]. This inhibition would lead to high
levels of dopaldehyde accumulating in the brain and could lead to the condensation of
dopamine with dopaldehyde to form 1-benzyl-THIQ, tetrahydropapaveroline [31].
THIQ's were originally isolated in plants under strongly acidic conditions by the
Pictet-Spengler condensation reaction [44]. It was subsequently demonstrated that THIQ
alkaloids can be formed under physiologic conditions of pH and temperature from the
condensation of aldehydes, such as acetaldehyde, with catecholamines, such as dopamine
and its N-methyl congener, epinephrine [45].
Davis and Walsh found that THP could be formed in vitro by incubating rat brain
stem homogenates rich in dopamine, with acetaldehyde and NADH, which is used as a
cofactor to retard the further metabolism of acetaldehyde [31]. The presence of THP in
rat brain was verified by infrared spectroscopy, gas chromatography, and thin-layer
chromatography [29-31]. Other researchers used thin-layer chromatography to
demonstrate the formation of THIQ alkaloids in vitro by perfusing bovine adrenal gland
with dilute acetaldehyde solutions [32]. This hypothesis was also supported by reports
that THP occurred in vivo in the brains of rats [33, 34, 46] and humans [35, 36, 47, 48].
Thus, buildup of THP following alcohol intake, might have pharmacological effects
relevant to the etiology of alcoholism.
Although the majority of ethanol is metabolized by alcohol dehydrogenase,
catalase, a ubiquitous enzyme found in large amounts in peroxisomes, can oxidize
ethanol as a co-substrate with hydrogen peroxide to yield water and acetaldehyde [49].
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Hydrogen peroxide is produced in brain tissue when monoamine oxidase (MAO)
oxidizes biogenic amines. Thus, catalase can use hydrogen peroxide to metabolize
ethanol to acetaldehyde in the brain, resulting in a large concentration of acetaldehyde
localized at dopaminergic neurons [8].
Alternatively, acetaldehyde inhibits the degradation of dopamine to
dihydroxyphenylacetic acid. This increases the availability of aldehydes for participation
in a Pictet-Spengler condensation with intact dopamine. If aldehyde dehydrogenase is
occupied with the metabolism of acetaldehyde, the biogenic aldehyde could condense
with its parent amine, resulting in THP formation. In fact, a recent report has shown that
pharmacological inhibition of MAO-A reduced the volitional consumption of ethanol,
perhaps by preventing the formation of both biogenic aldehydes and acetaldehyde and
preventing the formation of the alkaloidal products [8].
Since THP is a precursor in the synthesis of morphine and other alkaloids in
Papaver somniferum, the opium poppy, it was suggested that the formation of THP might
contribute to the development of addiction by acting as a false transmitter or opiate
agonist [29, 31, 50]. Additionally, THP might be further metabolized to form the opiates
themselves. Figure 9 shows this proposed "skewed" metabolism of dopamine resulting in
the formation of THP and hypothesized pathways (appearing as a dashed reaction arrow)
by which THP could be converted to opiate alkaloids and tetrahydroxyberberine
compounds [31]. Recently, S-(-)-THP was documented as being present in human brain
tissue at concentrations of 0.12 to 0.22 pmol/g [51]. Morphine has also been reported to
be endogenous to the CNS [52].
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Figure 9: Proposed Dopamine Metabolism Resulting in the Formation of
THP and Possibly Opiate Alkaloids [31]

While no conclusive evidence exists as yet for the formation of these opiate
alkaloids directly from THP in vivo, the efficacy of THP in eliciting a volitional drinking
response in experimental animals is well documented. Myers and Melchior reported
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initially that ICV infusions of THP would induce spontaneous volitional consumption of
relatively high concentrations of ethanol by Sprague-Dawley rats, an inbred strain that
normally avoids even low levels of ethanol [53-55]. Perfusion cannulae were implanted
in the lateral ventricle of rats by stereotaxic surgery. Figure 10 shows a cutaway diagram
of the lateral ventricles (marked as LV) of a rat. It should be noted that the lateral
ventricles serve as a reservoir of cerebrospinal fluid (CSF) for most of the medial
forebrain bundle.

Figure 10: A Sagittal Cutaway Diagram of a Rat Brain Showing the Lateral
Ventricle (LV) and Other Prominent Brain Features

The animals were then screened for alcohol preference using a three-bottle,
twelve-day test. The bottle positions were randomized every day. One bottle was empty,
the second contained water, and the third contained an ethanol solution in water. The
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alcohol concentration was gradually increased from 3% by volume to 30% by volume
over the twelve-day period [53]. Once baseline alcohol consumption for each animal was
established, the pool of experimental rats was divided into two groups. One group was
given ICV injections of a relatively high concentration of a racemic mixture of THP, and
the other given a low dosage of racemic THP. The S-(-)-isomer was also tested. The ICV
injections were made every fifteen minutes around the clock for fourteen days.
The rats were then screened for alcohol preference using the same initial method.
Drastic changes were noted in all of the rats' drinking preferences. Halfway through the
twelve-day protocol, rats that avoided even low concentrations of alcohol drank
increasing amounts [53]. Rats receiving the concentrated injections of THP increased
their alcohol consumption to half of their daily fluid intake [53]. Rats receiving the low
concentration doses of THP drank alcohol in concentrations of up to 25% by volume
[53]. These changes persisted until the end of the twelve-day protocol, with some
animals' blood ethanol levels reaching 0.2% [53]. Symptoms of intoxication such as
ataxia were noted in these animals that drank heavily, as well as symptoms of withdrawal
when these rats were not drinking ethanol, such as tremors, hyperactivity, rearing,
chewing, and jerking motions [53].
Another team of researchers [56] replicated this experiment. They confirmed that
ICV injections of 5.2 to 41.6 nmoles/day is sufficient to elevate a Sprague-Dawley rat's
alcohol consumption but that doses of 104 nmoles/day produced an aversion to ethanol
[56]. It was also reported that the highest volumes of alcohol consumption occurred when
the alcohol solution was 11% to 15% by volume [56]. This group of rats refused higher
concentrations of ethanol and their blood alcohol levels did not reach intoxication,
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although some animals did develop seizures [56]. No other symptoms of intoxication or
withdrawal were reported. THP-induced changes in alcohol preference in SpragueDawley rats have been found to be very long lasting [53, 56, 57]. They may even be
permanent, as animals injected with THP tested ten months later still exhibited a strong
alcohol preference [56].
These studies [53, 56-59] suggest a possible role for THP in the etiology of
ethanol craving. However, it remains to be seen whether THP acts as a false transmitter,
or as a morphine precursor. All available evidence revolves around the treatment of
experimental animals with morphine [60-72] or opiate antagonists such as naltrexone
[73-83] or naltrindole [84, 85]. Morphine has been shown to potentiate alcohol drinking
in rats with long term effects similar to those for THP-induced alcoholism [74]. Naloxone
and naltrindole have been reported to reduce the alcohol intake of rats that prefer alcohol
[63, 70, 74, 86]. So while no clear conclusions about the relationship between THP and
the opioidergic neural circuits in the brains of mammals can be drawn, the circumstantial
evidence points to some form of linkage between the two.
A number of abused drugs, which have independent pharmacological effects and
are otherwise classified as having separable sites and mechanism of action, all activate
the mesolimbic dopamine path. Drugs as diverse as cocaine, alcohol, nicotine, and
heroin have been shown to release dopamine from nerve terminals at the nucleus
accumbens (NAcc) of the basal forebrain [24, 26, 27, 87]. Pretreatment with naloxone, an
opioid antagonist which shows higher affinity for the \x opioid receptor [88, 89] or with
naltrindole, a 8 opioid receptor antagonist [90], attenuated the release of dopamine at the
NAcc evoked by administration of alcohol. Opiate antagonists, naltrexone and naloxone
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have also been found to suppress volitional alcohol consumption initiated by THP
infusion [74, 91, 92].
Mapping studies [93-95] have found that the ventral tegmental area (VTA) and
the nucleus accumbens are among the most behaviorally responsive sites to THP
microinfusion. Of the THIQ alkaloids, THP appears to be the most potent releaser of
dopamine at forebrain sites, including the NAcc [96]. More recently, microinjections of
THP into the VTA were found to augment extracellular efflux of dopamine from the core
of the NAcc [97] of high ethanol preferring (HEP) rats. Conversely, THP suppressed
dopamine efflux from the shell of the NAcc. Collectively, this evidence suggests that
THP might exert behavioral actions via modulation of the mesolimbic dopamine circuit.
While this hypothesis is supported by some investigators, others view THPinduced alcohol consumption in experimental animals as a pharmacological effect [98,
99]. These researchers call into question whether THIQ alkaloids are ever formed
endogenously in quantities sufficient to exert a significant effect on the behavior of the
animal. Still other researchers have called into question techniques used by investigators
that have been able to simulate alcoholism using THIQ's such as THIQ purity, surgical
techniques, dosing regimens, and animal care protocols [60, 100-102].
Nonetheless, there1 are few known compounds that exert such a profound effect on
volitional consumption of alcohol. At the least, these compounds may have utility in
probing sites and mechanisms in the central nervous system (CNS) involved in the
mediation or control of alcohol consumption.
Increases in alcohol consumption have been reported previously following central
injection of racemic THP as well as the (S)-enantiomer of THP [53]. Heretofore there
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have not been any published reports of alterations in alcohol preference induced by the
(R)-enantiomer of THP. The (S)-enantiomer has been proposed to be a major precursor
of morphine in the opium poppy [31]. It has been proposed that R-(+)-THP could be
converted to morphine via a racemization reaction [103-107] and low doses of morphine
have been found to promote alcohol consumption [64, 67, 70, 86, 108-110].
The (S)-enantiomer has been detected in the striatum of rats fed alcohol ad
libitum for 18 months, suggesting that a THP biosynthetic pathway exists in the
mammalian brain [111]. Moreover, a stereochemical analysis reported the presence of S(-)-THP, but not R-(+)-THP, in each of four human brains [51]. Thus, further
investigation of the (R)-enantiomer may yield additional pertinent information. If R-(+)THP has no effect on alcohol consumption, then one might expect S-(-)-THP to be twice
as effective as the racemic mixture.
On the contrary, prior reports have not found substantial differences in efficacy
between S-(-)-THP and racemic THP [53]. This suggests that the (R)-enantiomer should
be capable of stimulating alcohol consumption. Alternative to the hypothesis that
morphine is synthesized from the alkaloid, THP may act as an opiate agonist. Because of
the relative symmetry of the molecule, receptors may be unable to distinguish between
the two alkaloid isomers. In either scenario, one might expect each enantiomer to be
equally effective.
Experiments were conducted to re-evaluate whether, and to what degree, centrally
administered (±)-THP or (+)-THP might induce alcohol consumption. Additional
experiments evaluated whether simple repeated exposure to increasing concentrations of
alcohol might result in volitional drinking. Control groups were used to evaluate whether
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the stereotaxic procedure itself could impair the ability of the animal to discriminate
between alcohol and water.

CHAPTER II
EXPERIMENTAL
HPLC Resolution of the Enantiomers of Dihydroxyphenylalanine and Selected Salsolinol
Derivatives Using Sulfated P-Cyclodextrin as a Chiral Mobile Phase Additive
Reagents
Racemic and optically active salsolinol was prepared in our laboratory using
routes described in the literature [112]. Briefly, condensation of 3,4dimethoxyphenethylamine, the dimethoxy analog of dopamine, with acetic anhydride,
subsequent cyclization to l-methyl-6,7-dimethoxy-3,4-dihydroisoquinoline, followed by
reduction with sodium borohydride in ethanol gave salsolidine (Figure 11), the
dimethoxy analog of salsolinol.

Figure 11: Structure of (A) S-(-)-salsolidine; (B) R-(+)-salsolidine
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Demethylation of salsolidine in boiling concentrated hydrobromic acid gave
racemic salsolinol in analytical purity. Resolution of salsolidine followed by hydrobromic
acid catalyzed demethylation provided the optical isomers of salsolinol (Figure 12).

Figure 12: Structure of (A) S-(-)-salsolinoI; (B) R-(+)-salsolinoI
L-DOPA and racemic DL-DOPA (Figure 13) were obtained from commercial
sources (Sigma-Aldrich, St. Louis, MO).

Figure 13: Structure of (A) L-(-)-DOPA; (B) D-(+)-DOPA

The 3-carboxy-tetrahydroisoquinoline derivatives were prepared by reaction of LDOPA or racemic DL-DOPA with acetaldehyde to give, respectively, L-3-
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carboxysalsolinol and DL-3-carboxysalsolinol (Figure 14). Crystallization during workup provided the cis isomers as the major product [113].
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Figure 14: Condensations of (A) L-DOPA with Acetaldehyde to Form L-3Carboxysalsolinol; (B) D-DOPA with Acetaldehyde to Form D-3-Carboxysalsolinol
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Figure 15: Condensation of Dopamine with Pyruvic Acid to Form a Racemic Mix of
1-Carboxysalsolinol
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Racemic 1-carboxysalsolinol was synthesized in our laboratory using the reaction
of dopamine with pyruvic acid (Figure 15) as described in the literature [114].
Sulfated P-cyclodextrin (lot number 09718HR) was purchased from Aldrich
Chemical Co. Sulfated P-cyclodextrin is a cyclic sugar made up of seven glucose units
joined "head-to-tail" by alpha-1,4 linkages and has several (13-19) of the 21 inner and
outer rim hydroxyl groups converted to sulfate functionalities (Figure 16) [115-117].

Figure 16: Two Views of Sulfated P-Cyclodextrin (A) Side View; (B) Front as Seen
From the Smaller Diameter "Inner" Rim
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While direct molecular weight measurements were not available, carbonhydrogen analysis values provided by the vendor indicated an average molecular weight
of 3,000 Daltons.
Chromatography
An isocratic HPLC consisting of a micrometering pump (Rainin XLS), a valveloop injector (Rheodyne 7125), a variable UV detector (PE SpectroMonitor III) set to
measure absorbance at 280 nm, and a column oven (PE) were used in these studies.
Subambient column temperatures were maintained using stirred water baths.
Econosphere (4.6 mm ID x 250 mm, 5 jam ODS) and Adsorbosphere HS (4.6 mm ID x
150 mm, 3 um ODS) reversed-phase columns, purchased from Alltech Associates (Grace
Davison, Deerfield, IL) were employed. Econosphere columns were used primarily to
chromatograph salsolinol while Adsorbosphere columns, which have greater carbon
loading were used for the carboxylated substances.
Mobile phases consisted of 0.05 M phosphoric acid with the pH adjusted to a
value of 2.5 with sodium hydroxide. No adverse effects were noted from the use of
acidic mobile phases. Sulfated P-cyclodextrin was added as indicated in the text, to give
solutions of 0 to 2 mM. Concentrations greater than 1 mM for Econosphere columns and
2 mM for Adsorbosphere columns gave retention times very near the void retention time,
t0. Columns were equilibrated by passing 15 to 20 column volumes of mobile phase
through them before measurements were made.
Capacity factor, k', values were determined using the formula,
*' = (tr - to)/t0,

(Eqn. 1)
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where tr is the retention time of an analyte peak and t0 the retention time of an unretained
solute, obtained using injections of solutions of NaNC>3 or NaNC^.
Resolution, Rs, was determined using the equation,
Rs = 2At/(wj + w2),

(Eqn. 2)

where Atr is the difference in retention times between peaks and wi and W2 are the widths
of the peaks of the two enantiomers.
Selectivity, a, was calculated using the equation,

a = k'2/k'i,

(Eqn. 3)

where the k' values are for two peaks of interest.
Thermodynamics
Thermodynamics operating during the chromatographic process were assessed
using the van't Hoff expression [118, 119],
Ink' = (-AH/RT) + (AS/R) + ln(/>.

(Eqn. 4)

In this expression k' is the capacity factor, R the gas constant, AH and AS the enthalpy
and entropy of transfer of the solute from the mobile to the stationary phase, and § the
volume phase ratio of the stationary and mobile phases. The value of 0.385 was used to
approximatetyas suggested by Sander and Field for octadecasilyl (ODS) packings [120].
Approximately the same value for <>| was obtained when the method described by Cole
and Dorsey [118, 119, 121] was used together with values of percentage carbon loading
and mass of packing in a typical column obtained from the manufacturer.
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Plots of Ink' vs. 1/T were obtained. Slopes of these lines were taken to be equal to
-AH/R and the intercept to be equal to (AS/R) + ln<|). Uncertainties in (j) should affect all
AS measurements equally.
A Re-evaluation of the Role of Tetrahydropapaveroline in
Ethanol Consumption in Adult Male Sprague-Dawley Rats
Subjects
Thirty-one (31) male Sprague-Dawley rats (Harlan, Indianapolis, IN) obtained
from the Frederick, MD plant, weighing between 280 and 340 g at the time of surgery,
were used for this experiment. Animals were housed individually in hanging 11 inch by
15 inch wire cages on a reversed 12:12 light/dark cycle with light onset at 20:00. Food
was available ad libitum. Room temperature was maintained at 23 ± 1 °C. All
procedures involving animals were conducted in accordance with the NIH Guidelines for
the Care and Use of Laboratory Animals and the guidelines set forth by the Institutional
Animal Care and Use Committee (IACUC) of the University of Southern Mississippi
(APPENDIX).
Drug Preparation
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Artificial cerebrospinal fluid was used as a vehicle solution for all experimental
injections. A liter of artificial cerebrospinal fluid (aCSF) was made containing 7.46 g
NaCl, 0.19 g KC1, 0.14 g CaCl2, and 0.19 g MgCl2 dissolved in deionized water to which
was added 0.1 g ascorbic acid to retard the oxidation of THP. The aCSF was filtered
through a 0.2 urn nylon filter. The THP used in these experiments was synthesized in
our laboratory (Figure 17) [122-124]. Optically pure R-(+)-THP was synthesized in our
laboratory by Kenneth D. McMurtrey using established methods [125].
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Figure 17: Synthesis of Racemic Tetrahydropapaveroline Hydrobromide
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NMR Analysis
A 350 MHz Bruker NMR was used to obtain proton nuclear magnetic resonance
spectra for R-(+)-THP in D2O to obtain proof positive that our sample is in fact THP.
Chiral and Achiral HPLC Analysis
Samples of synthesized R-(+)-THP were chromatographed using both achiral and
chiral reversed phase HPLC with a UV detector. An isocratic HPLC consisting of a
micrometering pump (Rainin XLS), a valve-loop injector (Rheodyne 7125), and a
variable UV detector (PE SpectroMonitor III) set to measure absorbance at 280 nm. The
columns used were common octadecasilyl Luna (4.6 mm ID x 150 mm, 5um ODS-2),
and Prodigy (4.6 mm ID x 150 mm, 5um ODS-2) reversed-phase columns, purchased
from Phenomenex via Alltech Associates.
The mobile phase used for achiral analysis was 75 % 0.05 M phosphoric acid:
25% acetonitrile with the pH adjusted to a value of 2.5 with sodium hydroxide. The
mobile phase used for chiral analysis was 90 % 0.05 M phosphoric acid: 10% methanol
with the pH adjusted to a value of 3.0 with sodium hydroxide. S-(3-CD was then added to
this mobile phase in the amount of 2.0 g/L. These achiral and chiral mobile phases were
used in concert to assay both the identity and the enantiomeric excess of our R-(+)-THP
sample. In each case, the column was equilibrated by passing 15 to 20 column volumes
of mobile phase through it before measurements were made.
Grouping of Experimental Animals
The Sprague-Dawley rats were split into experimental groups. Animals in one
group received one of two doses of racemic THP in the amount of 0.65 ug/uL (n=6) or
1.3 ug/uL (n=4) in aCSF. All other reagents were purchased from Sigma (St. Louis,

MO). A counterpart solution of (+)-THP was prepared in a similar fashion. A second
group of animals received one of two doses of the (+)-THP, either 0.66 ng/uL (n=8) or
1.4 |ag/uL (n=4) in aCSF.

Controls received either aCSF containing no racemic THP or

(+)-THP, or no injections at all (n=9).
Alcohol Preference Testing
This experiment utilized the two-choice, three-bottle free access paradigm [126]
of exposure to incremental concentrations of alcohol (3 to 30% over twelve days). Three
calibrated 100 mL drinking tubes were positioned equidistantly at the front of each
animal's cage. One tube contained a solution of ethanol in which the concentration was
increased daily in the following manner: 3, 4, 5, 6, 7, 9, 11, 13, 15, 20, 25, and 30
percent alcohol by volume. Each solution was prepared with 95% ethanol (Everclear
drinking spirits) and distilled water. A second tube contained only water and the third
tube was empty.
These tubes were rotated each day according to a predetermined random sequence
to prevent the development of a position habit. By raising the concentration of the
ethanol offered, a baseline preference or aversion was established for each animal. Daily
measures of alcohol and water consumption were taken at 16:00. To evaluate the
possibility of fluid loss due to evaporation, an empty cage was fitted daily with the
appropriate fluids. Metal trays lined with newsprint were carefully inspected (and
replaced) daily for evidence of fluid spillage. Loss of fluid due to evaporation and
spillage was negligible.

Intraventricular Administration ofTHP
Each rat was anesthetized with ketamine: xylazine anesthesia (25:5 mg/kg or 1
mL/kg body weight; IP Figure 18) prior to stereotaxic surgery.

Figure 18: Intraperitoneal (IP) Injection of Anesthetic

Once anesthesia was confirmed via tail and foot pinch, the animal's head was
shaved and placed into a Kopf stereotaxic instrument (Figure 19) with the head centered
and the incisor bar set 3.0 mm above the interaural line.
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Figure 19: Schematic of a Kopf Stereotaxic Surgical Instrument

A stainless steel (22 ga., 13 mm in length) guide cannulae (Small Parts Inc.,
Miami Lakes, FL) was affixed to the probe holder of the Kopf apparatus. A small (ca. 1.5
inches) longitudinal incision was made in the scalp with a scalpel. The incision was held
open by hemostats. The fascia was then scraped away to reveal the skull. The skull is
wiped and dried with surgical gauze and any bleeding is stopped with a surgical cautery
(Aaron, Inc.).
The tip of the guide cannula was placed at bregma, a landmark feature of the skull
where the sagittal and coronal sutures meet (Figure 20).

Figure 20: Schematic of Landmark Features Found on the Rat Skull

Once bregma was located, the guide cannula tip was positioned above the lateral
ventricles according to Paxinos and Watson [127]. The coordinates from bregma were:
AP -0.5 mm; ML 1.5 mm; flat skull [127]. A mark was made at this point with a No. 2
pencil. A burr hole was drilled through the skull at this mark. The guide cannula was
swung aside on the boom arm and small surgical anchor screws (available from Small
Parts, Inc.) were inserted into the calvarium (Figure 21).
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Figure 21: Photograph of Placement of Stereotaxic Anchor Screws

The guide cannula was inserted into the skull through the burr hole and lowered
3.0 mm to the lateral ventricle of the animal [127]. Cranioplastic cement (Lang Dental)
was packed around the screws and guide cannulae in a pedestal shape to fix them all in
place. The incision was then closed around the pedestal with standard silk surgical
sutures.
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ICV Injections
Dummy cannulae (28 ga. stainless steel tubing from Small Parts, Inc.) were
prefitted to extend 0.5 mm beyond the tip of the guide cannula so that the tip of the
injection cannula rested in the lumen of the lateral ventricle. This prefitted 13.5 mm
length of 28 ga. stainless steel stylet was then inserted into the guide cannulae to prevent
obstructions. Injection needles of the same length and material were attached by
polyethylene tubing to a 50 uL tuberculin HPLC syringe. An automated Harvard
Apparatus Model PHD 2000 (South Natick, MA) syringe pump was used to deliver
intracerebroventricular (ICV) infusions of drug (or vehicle) in a volume of 5 uL per
infusion over two minutes. Each animal received two injections (09:00 and 16:00) per
day for three consecutive days. This dosing regimen has been shown previously with
THP to induce significant increases in alcohol consumption [113]. The first injection
commenced after a seven day post-surgery recovery period.
Alcohol Preference Test Scheduling
A twelve-day alcohol preference test was administered prior to the surgery. A
second twelve-day alcohol preference post-test was given following the three injection
days. In a subset of animals, three twelve-day tests were conducted: one sequence prior
to surgery, a second sequence after surgery but prior to central injections, and the third
sequence following three days of injections. In a subset of animals (n=15) that had been
treated with either (±)-THP or (+)-THP, volumetric water and alcohol consumption was
recorded every four hours around the clock to evaluate the distribution of alcohol and
water consumption over the course of a 24 hour period.
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Standard histological techniques were used to verify placement of guide cannulae.
All animals were sacrificed with a lethal overdose of sodium pentobarbital (Nembutal,
100 mg/kg BW), and perfused intracardially with 0.9% saline and 10% phosphatebuffered formalin. The brains were removed and stored in formalin for at least 24 hours.
Serial coronal sections (40 urn) were made in a cryostat (Microm HM 505 N) at -30 °C
through the site of implant onto gelatinized glass slides which were stained with cresyl
violet dye, then coverslipped. Cannula tip placements were visually compared to line
drawings from a stereotaxic atlas [127].
Statistical Analyses
All analyses were conducted using SPSS software. All values are expressed as
mean ± SEM. The a level of significance used for all statistical tests was/? < 0.05. A
one-way ANOVA for independent groups was used to compare the three control
conditions: vehicle-treated animals, sham-operated animals, and naive animals. A
mixed-model ANOVA (drug treatment over days) was used to analyze the effect of drug
treatment. The Huyn-Feldt correction was used since there was a violation of the
assumption of sphericity. Tukey's HSD post-hoc tests were used to compare treatment
conditions. To evaluate whether differences in alcohol consumption were significant on
each day, 95% confidence intervals were determined around the mean of the control
condition for each day. To evaluate whether repeated exposure to alcohol caused any
alteration in alcohol consumption, a one-way ANOVA for repeated measures was used
on animals that had completed three consecutive twelve-day preference tests without
receiving a drug treatment.
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A Re-evaluation of the Role of Tetrahydropapaveroline in
Ethanol Consumption in Another Population of Adult Sprague-Dawley Rats
Subjects
Subsequent to the first round of treatments performed on rats obtained from the
Frederick, MD plant, ten (10) male Sprague-Dawley rats (Harlan, Indianapolis, IN) from
the Prattville, AL plant weighing between 280 and 340 g at the time of surgery, were
used for this experiment. All conditions with regards to housing, light cycle, temperature,
and animal care were identical to the previous ICV experiment involving rats obtained
from the Harlan site in Frederick, MD. All procedures involving animals were conducted
in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals and
the guidelines set forth by the Institutional Animal Care and Use Committee (IACUC) of
the University of Southern Mississippi (APPENDIX).
Drug Preparation
Artificial cerebrospinal fluid was used as a vehicle solution for all experimental
injections. A liter of artificial cerebrospinal fluid (aCSF) was prepared in the same
manner as the previous ICV experiment involving rats obtained from the Harlan site in
Frederick, MD. The aCSF was filtered through a 0.2 um nylon filter. The THP used in
these experiments was synthesized in our laboratory (Figure 17) [122-124]. Optically
pure R-(+)-THP was synthesized in our laboratory by Kenneth D. McMurtrey using
established methods [125]. All other reagents were purchased from Sigma (St. Louis,
MO).
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Grouping of Experimental Animals
One group of animals received a dose of racemic THP in the amount of 0.65
ug/uL in aCSF. A counterpart solution of R-(+)-THP was prepared in a similar fashion.
A second group of animals received a dose of aCSF containing (+)-THP in the amount of
0.67 ug/uL. Control animals received aCSF containing no THP.
Animals in the first group received racemic THP in the amount of 0.65 ug/uL in
aCSF (n=3). A counterpart solution of R-(+)-THP was prepared in a similar fashion. A
second group of animals received R-(+)-THP in the amount 0.67 ug/uL in aCSF (n=3).
Controls received either aCSF containing no THP (n=2), or no injections at all (n=2).
Alcohol Preference Testing
This experiment utilized the two-choice, three-bottle free access paradigm [126]
of exposure to incremental concentrations of alcohol (3 to 30% over twelve days). Three
calibrated 100 mL drinking tubes were positioned equidistantly at the front of each
animal's cage. One tube contained a solution of ethanol in which the concentration was
increased daily in the following manner: 3, 4, 5, 6, 7, 9, 11, 13, 15, 20, 25, and 30
percent alcohol by volume. Each solution was prepared with 95% alcohol (Everclear
drinking spirits) and distilled water. A second tube contained only water and the third
tube was empty. These tubes were rotated each day according to a predetermined
random sequence to prevent the development of a position habit. By raising the
concentration of the ethanol offered, a baseline preference or aversion was established for
each animal. Daily measures of alcohol and water consumption were taken at 16:00. To
evaluate the possibility of fluid loss due to evaporation, an empty cage was fitted daily
with the appropriate fluids. Metal trays lined with newsprint were carefully inspected
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(and replaced) daily for evidence of fluid spillage. Loss of fluid due to evaporation and
spillage was negligible.
Intracerebroventricular Administration ofTHP
Each rat was anesthetized with ketamine: xylazine anesthesia (25:5 mg/kg or 1
mL/kg body weight; IP) prior to stereotaxic surgery. Once anesthesia was confirmed via
tail and foot pinch, the animal was shaved and placed into a Kopf stereotaxic instrument
with the head centered and the incisor bar set 3.0 mm above the interaural line.
A stainless steel (22 ga., 13mm in length) guide cannulae (Small Parts Inc.,
Miami Lakes, FL) was affixed to the probe holder of the Kopf apparatus. A small (ca. 1.5
inches) longitudinal incision was made in the scalp with a standard surgical scalpel. The
incision was held open by hemostats. The fascia was then scraped away to reveal the
skull. The skull is wiped and dried with surgical gauze and any bleeding is stopped with a
surgical cautery.
The tip of the guide cannula was placed at bregma, a landmark feature of the skull
where the sagittal and coronal sutures meet. Once bregma was located, the guide cannula
tip was positioned above the lateral ventricles according to Paxinos and Watson [127].
The coordinates from bregma were: AP -0.5 mm; ML 1.5 mm; flat skull [127]. A mark
was made at this point with a No. 2 pencil. A burr hole was drilled through the skull at
this mark. The guide cannula was swung aside on the boom arm and small surgical
anchor screws (available from Small Parts, Inc.) were inserted into the calvarium.
The guide cannula was inserted into the skull through the burr hole and lowered
3.0 mm to the lateral ventricle of the animal. Cranioplastic cement (Lang Dental) was
packed around the screws and guide cannulae in a pedestal shape to fix them all in place.
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ICV Injections
Dummy cannulae (28 ga. stainless steel tubing from Small Parts, Inc.) were
prefitted to extend 0.5 mm beyond the tip of the guide cannula so that the tip of the
injection cannula rested in the lumen of the lateral ventricle. This prefitted 13.5 mm
length of 28 ga. stainless steel stylet was then inserted into the guide cannulae to prevent
obstructions. Injection needles of the same length and material were attached by
polyethylene tubing to a 50 uL tuberculin HPLC syringe. An automated Harvard
Apparatus Model PHD 2000 (South Natick, MA) syringe pump was used to deliver
intracerebroventricular (ICV) infusions of drug (or vehicle) in a volume of 5 uL per
infusion over 2 minutes. Each animal received two injections (09:00 and 16:00) per day
for three consecutive days. This dosing regimen has been shown previously with THP to
induce significant increases in alcohol consumption [113]. The first injection
commenced after a seven day post-surgery recovery period.
Alcohol Preference Test Scheduling
A twelve-day alcohol preference test was administered prior to the surgery. A
second twelve-day alcohol preference post-test was given following the three injection
days. In a subset of animals, three twelve-day tests were conducted (n=T0): one
sequence prior to surgery, a second sequence after surgery but prior to central injections,
and the third sequence following three days of injections. In a subset of animals (n=15)
that had been treated with either THP racemate or R-(+)-THP, volumetric water and
alcohol consumption was recorded every four hours around the clock to evaluate the
distribution of alcohol and water consumption over the course of a 24 hour period.
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Standard histological techniques were used to verify placement of guide cannulae.
All animals were sacrificed with a lethal overdose of sodium pentobarbital (Nembutal,
100 mg/kg BW), and perfused intracardially with 0.9% saline and 10% phosphatebuffered formalin. The brains were removed and stored in formalin for at least 24 hours.
Serial coronal sections (40 urn) were made in a cryostat (Microm HM 505 N) at -30 °C
through the site of implant onto gelatinized glass slides which were stained with cresyl
violet dye, then coverslipped. Cannula tip placements were visually compared to line
drawings from a stereotaxic atlas [127].
Statistical Analyses
All analyses were conducted using SPSS software. All values are expressed as
mean ± SEM. The a level of significance used for all statistical tests was p < 0.05. A oneway ANOVA for independent groups was used to compare the control conditions. A
mixed-model ANOVA (drug treatment over days) was used to analyze the effect of drug
treatment. The Huyn-Feldt correction was used since there was a violation of the
assumption of sphericity. Tukey's HSD post-hoc tests were used to compare treatment
conditions. To evaluate whether differences in alcohol consumption were significant on
each day, 95% confidence intervals were determined around the mean of the control
condition for each day. To evaluate whether repeated exposure to alcohol caused any
alteration in alcohol consumption, a one-way ANOVA for repeated measures was used
on animals that had completed three consecutive twelve-day preference tests without
receiving a drug treatment.
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An Evaluation of the Role of 2,3,10,11 -Tetrahydroxyberbine in
Ethanol Consumption in Adult Male Sprague-Dawley Rats
Subjects
Eleven (11) male Sprague-Dawley rats (Harlan, Indianapolis, IN) obtained from
the Frederick, MD plant, weighing between 280 and 340 g at the time of surgery, were
used for this experiment. All conditions with regards to housing, light cycle, temperature,
and animal care were identical to the previous experiments involving ICV injections of
THP. All procedures involving animals were conducted in accordance with the NIH
Guidelines for the Care and Use of Laboratory Animals and the guidelines set forth by
the Institutional Animal Care and Use Committee (IACUC) of the University of Southern
Mississippi (APPENDIX).
Drug Preparation
Artificial cerebrospinal fluid was used as a vehicle solution for all experimental
injections. A liter of artificial cerebrospinal fluid (aCSF) was prepared in the same
manner as the previous experiments involving ICV injections of THP. Ascorbic acid was
added in the amount of 0.1 g to retard the oxidation of THB (structure depicted in Figure
22). The aCSF was filtered through a 0.2 um nylon filter. The THB used in these
experiments was synthesized in our laboratory according to methods found in the
literature [123, 124]. All other reagents were purchased from Sigma (St. Louis, MO).
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Figure 22: Structure of THB

Animals received a dose of THB in the amount of 0.65 [ig/[iL in aCSF (n=6) in
the form of 5 ^L over a period of two minutes. Control animals received aCSF containing
no THB in the same volume and time period (n=4).
Alcohol Preference Testing
This experiment utilized the two-choice, three-bottle free access paradigm [126]
of exposure to incremental concentrations of alcohol (3 to 30% over twelve days). Three
calibrated 100 mL drinking tubes were positioned equidistantly at the front of each
animal's cage. One tube contained a solution of ethanol in which the concentration was
increased daily in the following manner: 3, 4, 5, 6, 7, 9, 11, 13,15, 20, 25, and 30
percent alcohol by volume. Each ethanol solution was prepared with 95% alcohol
(Everclear drinking spirits) and distilled water. A second tube contained only water and
the third tube was empty. These tubes were rotated each day according to a
predetermined random sequence to prevent the development of a position habit.
By raising the concentration of the ethanol offered, a baseline preference or
aversion was established for each animal. Daily measures of alcohol and water
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consumption were taken at 16:00. To evaluate the possibility of fluid loss due to
evaporation, an empty cage was fitted daily with the appropriate fluids. Metal trays lined
with newsprint were carefully inspected (and replaced) daily for evidence of fluid
spillage. Loss of fluid due to evaporation and spillage was negligible.
Intracerebroventricular Administration ofTHB
Stainless steel (22 ga., 13mm in length) guide cannulae (Small Parts, Miami
Lakes, FL) were stereotaxically implanted into the right lateral ventricle of each rat under
ketamine: xylazine anesthesia (25:5 mg/kg body weight; IP) seven days prior to the
beginning of central injections. The coordinates from bregma were AP -0.5 mm; ML 1.5
mm; flat skull [127]. After anchor screws (available from Small Parts, Inc.) were
inserted into the calvarium, cranioplastic cement (Lang Dental) was packed around the
screws and guide cannulae to fix them in place.
Dummy cannulae (28 ga. stainless steel tubing, Small Parts, Inc.) were prefitted
to extend 0.5 mm beyond the tip of the guide cannula so that the tip of the injection
cannula rested in the lumen of the lateral ventricle. These prefitted 13.5 mm lengths of 28
ga. stainless steel stylets were then inserted into the guide cannulae to prevent
obstructions.
Injection needles of the same length were attached by polyethylene tubing to a
50 pL tuberculin HPLC syringe. An automated Harvard Apparatus Model PHD 2000
(South Natick, MA) syringe pump was used to deliver intracerebroventricular (ICV)
infusions of drug (or vehicle) in a volume of 5 uL per infusion over 2 minutes. Each
animal received two injections (09:00 and 16:00) per day for three consecutive days.
This dosing regimen has been shown previously with THP to induce significant increases
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in alcohol consumption [113]. The first injection day commenced after a seven day postsurgery recovery period.
A twelve-day alcohol preference test was administered prior to the surgery. A
second twelve-day alcohol preference post-test was given following the three injection
days. Standard histological techniques were used to verify placement of guide cannulae.
All animals were sacrificed with a lethal overdose of sodium pentobarbital (Nembutal,
100 mg/kg BW), and perfused intracardially with 0.9% saline and 10% phosphatebuffered formalin. The brains were removed and stored in formalin for at least 24 hours.
Serial coronal sections (40 urn) were made in a cryostat (Microm HM 505 N) at -30 ° C
through the site of implant onto gelatinized glass slides which were stained with cresyl
violet dye, then coverslipped. Cannula tip placements were visually compared to line
drawings from a stereotaxic atlas [127].
Statistical Analyses
All analyses were conducted using SPSS software. All values are expressed as
mean±SEM. The a level of significance used for all statistical tests was p< 0.05. A
one-way ANOVA for independent groups was used to compare the control conditions. A
mixed-model ANOVA (drug treatment over days) was used to analyze the effect of drug
treatment. The Huyn-Feldt correction was used since there was a violation of the
assumption of sphericity. Tukey's HSD post-hoc tests were used to compare treatment
conditions. To evaluate whether differences in alcohol consumption were significant on
each day, 95% confidence intervals were determined around the mean of the control
condition for each day. To evaluate whether repeated exposure to alcohol caused any
alteration in alcohol consumption, a one-way ANOVA for repeated measures was used
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on animals that had completed three consecutive twelve-day preference tests without
receiving a drug treatment.
Investigation of the Effects of Ethanol Consumption on Tetrahydropapaveroline Levels in
the Cerebrospinal Fluid of Adult Male Sprague-Dawley Rats Using Microdialysis and
High Pressure Liquid Chromatography with Electrochemical Detection
Subjects
Three (3) male Sprague-Dawley rats (Harlan, Indianapolis, IN), weighing
between 280 and 340 g at the time of surgery, were used for this experiment. Animals
were housed individually in hanging 11 inch X 15 inch wire cages on a reverse 12:12
light/dark cycle with light onset at 20:00. Food was available ad libitum. Room
temperature was maintained at 23 ± 1 ° C. All procedures involving animals were
conducted in accordance with the NIH Guidelines for the Care and Use of Laboratory
Animals and the guidelines set forth by the Institutional Animal Care and Use Committee
(IACUC) of the University of Southern Mississippi (APPENDIX).
Implantation of Microdialysis Probe Guide Cannulae
Stainless steel (21.5 ga., 13 mm in length) guide cannulae (Small Parts, Miami
Lakes, FL) were stereotaxically implanted into the right lateral ventricle of each rat under
ketamine: xylazine anesthesia (25:5 mg/kg body weight; IP) seven days prior to the
beginning of microdialysis sampling. The coordinates from bregma were AP -0.5 mm;
ML 1.5 mm; flat skull [127]. After anchor screws (available from Small Parts, Inc.) were
inserted into the calvarium, cranioplastic cement (Lang Dental) was packed around the
screws and guide cannulae to fix them in place.

Dummy cannulae (28 ga. stainless steel tubmg, Small Parts, Inc.) were prefitted to
extend 0.5 mm beyond the tip of the guide cannula so that the tip of the dummy cannula
would rest in the lumen of the lateral ventricle. These prefitted 13.5 mm lengths of 28 ga.
stainless steel stylets were inserted into the guide cannulae to prevent obstructions.
Microdialysis Recovery Determination
In order to determine the optimal flow rate for microdialysis experiments, a
simulation of microdialysis conditions was conducted. A 2mL aliquot of a 0.69 uM
solution of THP in aCSF was placed in a 3 mL vial for each flow rate trial. A CMA/11
microdialysis probe with a 2.0 mm cuprophane dialysis membrane having a 6,000 Dalton
cutoff range was placed in the 0.69 uM "parent" solution and perfused with aCSF using a
Harvard Apparatus syringe pump at 0.5, 1.0, and 1.5 uL/minute. Six 20 uL samples of
dialysate were collected at each flow rate and THP concentration of each dialysate
sample was determined using high pressure liquid chromatography with an
electrochemical detector.
The HPLC apparatus used consisted of a Rheodyne 7125 injector valve, a Rainin
XLS delivery pump, a Econosphere (4.6 mm ID x 250 mm 5 urn ODS) HPLC column,
and a BAS LC-3 amperometric detector using a glassy carbon electrode cell. The
potential of the working electrode was set to 700 mV. The mobile phase consisted of
0.05M NH4H2PO4 with a 5% acetonitrile component with a pH of 4.00.
Microdialysis Sampling of Rat CSF
An animal holding pen was constructed from a large (ca. 3.5 gallon) plastic
planting pot available at any garden or home improvement store. The drain holes were
blocked with a large paper plate and appropriate bedding and food pellets were placed in
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the pen. Two iron ring stands were placed on either side of the holding pen and a crossbar
transecting the diameter of the pen was suspended approximately six inches above the
rim of the pen to act as a tether point for polyethylene tubing and dialysate collection
vials (Figure 23). A drinking tube filled with water was clamped to one iron ring stand
and lowered into the pen to provide animals with fluid ad libitum.

Figure 23: Microdialysis Holding Pen and Support Setup

A CMA/11 microdialysis probe was connected to a Harvard Apparatus syringe
pump using approximately one meter of polyethylene tubing and CMA tubing
connectors. The CMA/11 microdialysis probe is tipped with a 2.0 mm cuprophane
membrane that allows the diffusion of neurotransmitters into the perfusate solution, aCSF
prepared in the same fashion as the aCSF used for ICV injections.

The syringe pump was set to deliver aCSF to the probe at 1.0 uL/min. After a
visual inspection to insure that the dialysate fluid ran clear and the membrane was not
perforated, approximately 200 cm of polyethylene collection tubing was connected using
CMA tubing connectors. After a 30 minute equilibration period, the collection of dialysis
samples began. Dialysate was collected from each animal in five 20 minute intervals.
After collection of baseline THP samples for assessment of basal THP levels, rats were
force fed via a gavage tube 5 mL of 20% ethanol in distilled water ten minutes prior to
their introduction into the microdialysis chamber and subsequent insertion of the
CMA/11 probe.
HPLC Analysis of Ventricular CSF Using Amperometric Electrochemical Detection
The HPLC apparatus used consisted of a Valco rotary injector valve, a LDC
delivery pump, an Econosphere (4.6 mm ID x 250 mm, 5 urn ODS) HPLC column, and
an amperometric detector using a glassy carbon electrode cell. Dr. Newton Fawcett of
the University of Southern Mississippi chemistry and biochemistry department
constructed this detector. This amperometric detector was used because of its excellent
signal to noise ratio. Dr. Fawcett used high-grade gold connector pins, which last much
longer and yield a better signal than conventional manufacturer components, in the circuit
design. The potential of the working electrode was set to 700 mV. The mobile phase
consisted of 0.05M NH 4 H 2 P0 4 buffered to a pH of 3.00 with NaOH. The column was
flushed after each chromatographic run until THP was no longer detectable to avoid
carryover into the next sample.

CHAPTER III
EXPERIMENTAL RESULTS, DISCUSSION, AND CONCLUSIONS
Experimental Results on HPLC Resolution of the Enantiomers of
Dihydroxyphenylalanine and Selected Salsolinol Derivatives Using Sulfated PCyclodextrin as a Chiral Mobile Phase Additive
Deng and co-workers used P-cyclodextrin (P-CD) in combination with ionpairing reagents such as sodium heptyl sulfate to separate the stereoisomers of salsolinol
[128-131]. They reported modest maximum selectivity of approximately 1.08. This
experiment examined the use of commercially available sulfated P-cyclodextrin (S-PCD) and demonstrates that it efficiently separates the stereoisomers of salsolinol when
used alone without heptane sulfate or other ion-pairing reagents.
Indeed, S-P-CD yields a selectivity of approximately 1.08 at even the very low
concentration of 0.1 mM, whereas concentrations of about 15 mM are required for P-CD
and these chiral separations are successful only in the presence of an ion-pairing
reagent[128-131]. S-P-CD is capable of much greater degrees of separation of salsolinol
enantiomers than P-CD. This experiment yielded an a value of 1.59 and a resolution of
3.5 for R-(+)- and S-(-)-salsolinol using 1 mM S-P-CD concentration without an ionpairing reagent. Greater concentrations of S-P-CD should provide even greater a and Rs
values. The limiting factor for salsolinol appears to be the very low retention times
accompanying the use of higher concentrations of the chiral selector. With a 1 mM
concentration of S-P-CD the value of k' for (+)-SAL is less than 1.
Stoichiometry of the complex formed between SAL stereoisomers and sulfated pcyclodextrin appears to be 1:1. A study of the effects of increasing S-P-CD concentration
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on retention of the stereoisomers of SAL indicates that variation of the reciprocal of the
capacity factors of R-(+)-, and S-(-)-SAL are linear (Figure 24). This is the relationship
expected if SAL and S-P-CD form a 1:1 complex [132].
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Figure 24: Plot of the Reciprocal of the Capacity Factor Versus Varying
Concentrations of Chiral Mobile Phase Additive
L-DOPA, D-DOPA and related carboxylated derivatives of salsolinol were
chromatographed on a Cis reversed phase column with an aqueous mobile phase
containing varying amounts of the chiral selector, sulfated P-cyclodextrin (S-P-CD). In
contrast to the linear relationships observed in the case of SAL stereoisomers, the
carboxyl-substituted compounds give nonlinear curves when 1/k' for these materials is
plotted against S-P-CD concentration (Figure 25). This nonlinearity is taken as evidence
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that the equilibrium system between S-p-CD and the carboxylated compounds are more
complex than that operating for salsolinol [132].

Figure 25: Plot of the Reciprocal of Capacity Factor of Chiral Separations of DOPA,
1-CSAL, and 3-CSAL Versus Chiral Mobile Phase Additive
In an attempt to gain some insight into the mechanisms that may be operating, the
effects of temperature on retention of the various carboxylated compounds were
investigated with a mobile phase containing 2 mM S-P-CD. Representative
chromatograms of resolution of the compounds studied are given in Figure 26.
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Figure 26: Representative Chromatograms of Chiral Separations of (A) SAL
at 20 °C; (B) DOPA at 35 °C; (C) 3-CSAL at 35 °C; (D) 3-CSAL at 0 °C; (E) 1-CSAL
at 0 °C. All Chromatograms on Same Time Scale With Tick Marks at Five Minute
Intervals
Salsolinol separates well at room temperature (trace A) and 3-CSAL gives good
resolution at 35 °C (trace C). Resolution of D- and L-DOPA is not complete at 35 °C
(trace B), although resolution improves when the temperature of the column is decreased
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(not shown). Lower temperatures generally improve resolution. This improvement is
represented by chromatogram D which is the separation of D- and L-3-CSAL at 0 °C
with a resolution slightly greater than 5. In contrast 1-CSAL isomers are separated only
slightly (trace E). Even this degree of separation is achieved only at 0 °C.
The data obtained were used to prepare van't Hoff plots (Figure 27). The most
immediately obvious characteristic of these plots are the breaks in the curves immediately
below room temperature, approximately 15 °C to 20 °C. Curves between 20 °C and 35 °C
have different slopes and intercepts than those obtained from measurements between 0 °C
and 13 °C. Different slopes and intercepts indicate differences in AH and AS values.
When plotted seperately these two sections of the curve have differing slopes, indicating
different enthalpy and entropy values. The "low temperature" van't Hoff plot appears as
Figure 28. The "high temperature" van't Hoff plot appears as Figure 29.
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Van't Hoff curves for the compounds using a mobile phase that did not contain
the chiral selector were obtained and similar breaks were found. Thermodynamic data
obtained from the slopes and intercepts of the curves are given in Tables 1-4. As may be
seen, all thermodynamic variables are negative. Furthermore, absolute values for both
AH0 and AS0 increase when the temperatures used in their determinations decrease. In all
cases AH0 values are negative and thus favorable for retention, but in all cases AS0 values
are also negative and therefore unfavorable. Contributions by unfavorable entropy values
are more than offset by favorable enthalpy values.

Table 1: Thermodynamic Variables Associated With Chromatography of the Test
Substances with Mobile Phase Containing 2 mM S-P-CD Over Relatively High
Temperatures (20 °C-35 °C)
Substance
L-DOPA

AH°(kJ/mol)
- 17.7

AS°(J/Kmol)
-45.0

D-DOPA

-16.5

-41.3

L-3-CSAL

-18.0

- 47.0

D-3-CSAL

-16.3

-43.3
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Table 2: Thermodynamic Variables Associated With Chromatography of the Test
Substances with Mobile Phase Containing 2 mM S-P-CD Over Relatively Low
Temperatures (0 °C-13 °C)
Substance
L-DOPA

AH°(kJ/mol)
-30.7

AS°(J/Kmol)
-87.8

D-DOPA

-29.3

- 84.0

L-3-CSAL

-36.0

- 107.8

D-3-CSAL

-35.2

- 108.0

Table 3: Thermodynamic Variables Associated With Chromatography of the Test
Substances with Mobile Phase Containing no Chiral Selector S-P-CD Over
Relatively High Temperatures (20 °C-35 °C)
Substance
DOPA

AH°(kJ/mol)
-18.4

AS°(J/Kmol)
-49.1

3-CSAL

-18.7

-50.0

1-CSAL

-15.6

-39.2

SAL

-15.2

-33.2

Table 4: Thermodynamic Variables Associated With Chromatography of the Test
Substances with Mobile Phase Containing no Chiral Selector S-P-CD Over
Relatively Low Temperatures (0 °C-13 °C)
Substance
DOPA

AH" (kJ/mol)
-33.7

AS" (J/Kmol)
- 100.8

3-CSAL

-34.9

-104.8

1-CSAL

-34.0

-103.1

SAL

-22.7

- 57.8

The breaks in the van't Hoff curves are interpreted in terms of the retention model
developed by Dorsey and Dill [133]. These data indicate a phase transition in the
stationary phase hydrocarbon chains occurring over approximately the 15 °C to 20 PC
range. Such phase transitions in re versed-phase stationary phases are relatively well
known. They have been described as a "reversible melting-like transition of long-chain
hydrocarbon ligands" which occur in high bonding density monomeric silica based Cis
packings in the vicinity of room temperature [119, 134, 135].
At higher temperatures the extended chains allow relatively easy penetration of
solute molecules into the stationary phase while the more compacted chains at lower
temperature provide less opportunity of solute penetration. The effect is most clearly
seen in the entropy values. Entropies of retention are double in the negative unfavorable
direction at lower temperatures than they are at higher ones. Absorption of solute
molecules by the stationary phase at the lower temperature conformation is more costly
in terms of the entropy of chain ordering if the chains are more compact at these
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temperatures.
The crural compound S-P-CD appears to be an efficient and cost effective chiral
selector for resolution of salsolinol and 3-carboxysalsolinol optical isomers. However, it
is less effective for D- and L-DOPA, giving complete resolution only at subambient
temperatures. It is least effective of all for 1-carboxysalsolinol. Retention of these
materials is promoted by favorable enthalpies which (except for the case of 1-CSAL)
more than make up for unfavorable changes in entropy.
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Experimental Results from ICV Injections of Relevant Compounds on Volitional Ethanol
Consumption in Adult Male Sprague-Dawley Rats
THP Characterization by Proton NMR
A one dimensional proton NMR scan of the sample of R-(+)-THP in D2O yielded
the following spectrum (Figure 30).
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Figure 30: Proton NMR Spectrum and Peak Assignments for R-(+)-THP
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Protons attached to aryl moieties (positions "a", "b", "g", "h", and "i") exhibit the
greatest chemical shift and show as peaks from 6.7-6.5 ppm. The HDO peak from the
exchange of labile hydrogen between the analyte and D2O solvent appears, as expected,
as a large peak at approximately 4.7ppm. A chemical shift of approximately 4.45 ppm is
observed for the proton in the position "e". Proton "d" is heavily split and shows as a
multiplet from 3.3-3.1 ppm. Proton "c", attached to the nitrogen-containing portion of the
molecule, overlaps slightly with proton "f" at approximately 2.8-2.7 ppm. These
interpretations match those obtainable from the Sadtler Index [136] and those obtained by
previous researchers [137, 138]. Hence, the identity of this sample of synthesized
stereoisomer of THP is confirmed.
HPLC Analysis in Achiral and Chiral Environments
Injection of samples of R-(+)-THP and racemic THP onto a commercially
available Cjg ODS HPLC column with an achiral mobile phase yielded the following
chromatograms (Figure 31). Trace A is a sample of R-(+)-THP dissolved in a solution of
identical composition as the mobile phase with sodium nitrate added as a to marker. Trace
B is an identical solution that has been spiked with an additional aliquot of racemic THP.
The coelution of these compounds from this column indicates that the samples behave
identically in an achiral environment. This is indicative of extreme similarity in the
hydrophilic nature of these compounds.
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Figure 31: Achiral HPLC Chromatographs Showing Retention Times of (A)
NaN0 3 and R-(+)-THP; (B) NaNOs, R-(+)-THP, and Racemic THP

Additionally, samples of R-(+)-THP and racemic THP were injected onto a
commercially available Cis ODS HPLC column with an chiral mobile phase (2.0 g/L S-PCD) yielded the following chromatograms (Figure 32).
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Figure 32: Representative Chiral HPLC Chromatograms of (A) R-(+)-THP
and NaN0 3 ; (B) NaN0 3 and THP Racemate; (C) NaN0 3 , THP Racemate, and R(+)-THP

Chromatogram A is a sample of R-(+)-THP dissolved in an aliquot of mobile
phase with sodium nitrate added as a to marker. Trace B represents a sample of THP
racemate chromatographed under the same conditions. The two peaks in chromatogram B
proved to be of equal area after integration, verifying that the two THP stereoisomers are
present in equal proportions in the racemate. Chromatogram C depicts an equimolar
sample of R-(+)-THP and THP racemate.
Upon integration, the leftmost peak of R-(+)-THP has doubled in area. This
indicates that the sample of R-(+)-THP and the R-stereoisomer of the racemate coelute in
a chiral environment. These data, when coupled with the proton NMR spectra, confirm
the identification of both samples as authentic THP.
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The Effect of ICV Injections ofTHP on Ethanol Consumption in Adult Male SpragueDawley Rats Obtainedfrom the Frederick, MD Harlan Site
Only data from animals having cannulae tips within the right lateral ventricle or at
the dorsal rim of the ventricle were included in the statistical analysis. Histological 40 um
sections were made on a cryostat (Microm HM 505 N) at -30 °C and stained with cresyl
violet. These sections were visually inspected on a lightfield microscope. A
representative histological section is shown in Figure 33.

Figure 33: Representative Coronal Brain Section Showing Typical Cannula
Placement (Outlined Area Indicates Cannula Tract)
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The control condition in this experiment consisted of CSF-treated animals, shamoperated animals, and nai've animals. A one-way ANOVA for independent groups
revealed no significant differences in alcohol intake between these three control
conditions, F(2,6) = 2.21 A, p = 0.184. Hence, these data were collapsed into one control
condition. From this analysis, one can rule out the possibility that the surgical procedure
itself might affect an animal's preference for (or ability to discriminate between) the
tastes of alcohol and water.
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nmoles/day ICV Injections of R-(+)-THP and Racemic THP

The effect of acute ICV injections of (±)-THP or (+)-THP on the preference test is
shown in Figures 34 and 35. The effects of the lower doses (0.65 and 0.66 (ig/uL) of
either (±)-THP or (+)-THP on alcohol intake were strikingly different than the effects of
the higher doses (1.3 and 1.4 (ig/uL) of either compound. As a result, separate mixedmodel ANOVA's were conducted for the lower and higher doses of the alkaloids. For
the lower doses, the main effect of animals across days was significant, F(l 1,231 )=5.648,
/K0.001. The main effect of drug treatment was also significant, F(2,21)=9.139,
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/?<0.001. In addition, the interaction effect (drug treatment over days) was significant,
F(22, 231)=3.847,/K0.001.
The effects of lower doses of (±)-THP or (+)-THP are illustrated in Figure 34.
Post-hoc comparisons revealed a significant increase in consumption of absolute alcohol
following ICV administration of the lower dose (0.65 ug/uL) of (±)-THP,/?=0.002.
Compared to controls, the lower dose (0.66 ug/uL) of (+)-THP also significantly
enhanced alcohol intake, p=0.017. Differences in alcohol consumption between (±)THP-treated animals and (+)-THP-treated animals were not significant, ^=0.493.
The 95% confidence interval test determined that low doses of (±)-THP resulted
in a significant increase in intake of alcohol from 7%-13% concentrations of ethanol.
Low doses of (+)-THP significantly enhanced consumption of alcohol from 4%-l 1%
concentrations and again at 15%-20% concentrations. At no time did drug treatment
result in a decrease in alcohol consumption relative to control.
While lower doses of racemic THP induced a preference for alcohol across a midrange of ethanol concentrations, the magnitude of the increase was not as pronounced as
those observed in the initial reports of THP-induced drinking [53, 139]. This may be due
to differences in dosing regimen. For example, more dramatic increases have been
observed across a similar range of doses (i.e., 0.1-10.0 |ig/uL), perhaps because the
dosing regimen was extended throughout the entire 12-day preference test [53, 54, 74, 91,
95, 101, 140-143]. Although less dramatic, the data reported here indicates that repeated
central infusion of THP during the test period is not necessary to maintain a change in
alcohol preference.
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In contrast to the prominent effects of low doses, ICV administration of the higher
doses of (±)-THP (1.3 M.g/uL) and (+)-THP (1.4 ug/uL) did not significantly alter alcohol
consumption (Figure 35). A mixed-model ANOVA revealed that neither the main effect
of animals across days nor the main effects of drug treatment were significant.
Additionally, the interaction effect (drug treatment over days) was not significant.
A summary of the average g/kg ethanol dosage consumed by each experimental
group appears as Table 5. While these data are not as dramatic as those reported by other
researchers [53-55, 58, 74, 91, 93, 95, 97, 141, 144-148], they are compelling
nonetheless.

Table 5: Average Grams of Ethanol per Kilogram Body Weight Consumed by Each
Experimental Group Over the Course of the Entire ICV Experiment
Experimental Group

Number of Subjects

Mean g/kg

+THP (20 nmoles/day)

6

1.83 ±0.25

+THP (20 nmoles/day)

8

1.53 ±0.22

Control

9

0.69 ± 0.22

+THP (40 nmoles/day)

4

0.45 ±0.18

+THP (40 nmoles/day)

4

1.02 ±0.18

A subset of animals from the control condition was subjected to three consecutive
twelve-day alcohol preference tests due to the fact that previous researchers' report of
habituation [149]. A one-way ANOVA for repeated measures revealed no significant
differences in alcohol consumption among these animals, F(2,26)=0A52, p=0.642.
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Repeated exposure to escalating concentrations of alcohol solutions alone did not alter
alcohol intake. One can, therefore, rule out habituation or sensitization as possible
explanations for changes in patterns of alcohol consumption in this experiment.
In a subset of animals (n=17) treated with either (±)-THP or (+)-THP, alcohol and
water measurements were taken every four hours around the clock during the twelve-day
preference test (Figure 36). Most of the intake of both alcohol solutions and water
occurred during the nocturnal period, with more than a two-fold decline in consumption
of all fluid occurring immediately thereafter, in the first full four hours of light. Thus, it
may be assumed that rats do, in fact drink at a specific point in their circadian cycle.

Lights On

Lights Off

H20
EtOH

I
X

X
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10 pm
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Time of Day

Figure 36: Bar Graph Showing Fluid Consumption-Distribution For Four Hour
Periods Across Twelve-Day Ethanol Preference Tests
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Myers and associates have conducted numerous experiments demonstrating
volitional alcohol consumption following ICV or site-specific injections of THP, as well
as other THIQ alkaloids, in rats [150]. However, some investigators have not observed
any drinking following ICV injections of THP [102]. Even if THP-induced drinking does
occur, some investigators have expressed doubts concerning the potential relevance of
these data [99, 151, 152]. Moreover, there are few laboratories that have actually
confirmed the finding of an increase in alcohol consequent to THP administration [56,
95, 142]. In the present study, it was found that both (±)-THP and (+)-THP (0.65-0.66
ug/uL; ICV) induced significant increases in alcohol intake (Figure 34). Most of the
alcohol was consumed within an eight hour period.
The lack of effect of the higher doses (1.3-1.4 ug/uL; ICV) of either compound
was unexpected (Figure 35 or Table 5). Duncan and Deitrich reported enhanced
consumption of alcohol after ICV administration of THP at doses of 10.4 and 41.6
nmoles/day [56]. The doses used in the present study are 20 and 40 nmoles of THP per
day. The principle methodological difference between the two studies concerns the
dosing regimen. In contrast to the shortened dosing regimen used here, Duncan and
Deitrich gave injections of 0.02 ug/uL every 15 minutes around the clock, starting two
days prior to and continuing throughout the preference test [56]. Given the minimal
dosing regimen used in this study (i.e., two injections/day for three days), one might
expect a response to the higher of the two doses tested. Alcohol consumption, instead,
increased in response to the lower dose.
Other investigators have reported similar findings. Clow et al. [142] found that
the most marked behavioral response occurred in response to the lower of two doses (0.1
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ug compared to 1.0 ug) of THP. Even lower doses (50 ng) of THP, delivered
intraventricularly, have been shown to increase absolute intake of alcohol from 1.0 g/kg
to 3.5 g/kg/day using the same dosing regimen as the one utilized presently [141]. Sitespecific injections of picomolar concentrations of THP into limbic structures have been
found to enhance alcohol consumption [93, 94]. Thus, the efficacy of the lower dose of
either (±)-THP or (+)-THP in the present study was not surprising. Additionally, our
findings are consistent with prior reports [53, 56, 94, 139] which demonstrate that the
augmented drinking response does not depend on continuous THP infusion. Enhanced
drinking continues long after THP clearance.
Diminishing alcohol consumption at higher doses of THP has been reported
previously. Indeed, higher doses of THP are capable of attenuating alcohol consumption
[94]. An inverted U-distribution best describes the dose-response function [150], with
THP serving as an opiate agonist at lower doses and as an opiate antagonist at higher
doses [94]. This may explain the lack of response to higher doses of THP tested in the
present experiment. If relatively few injections of 1.3-1.4 ug/uL of THP are sufficient to
induce such a ceiling effect [56], then why would a more chronic treatment regimen
actually enhance alcohol intake? Perhaps a long-term alteration in receptor sensitivity
occurs. Alternatively, perhaps molecular alterations in signal transduction processes may
occur in response to chronic treatment with THP.
While increases in alcohol consumption have been reported previously following
ICV injection of (±)-THP and (-)-THP [53], this is the first known report of an increase in
alcohol consumption caused by (+)-THP. The magnitude of the response did not differ
significantly from the response to racemic THP. In fact, the response was extended to
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higher concentrations (15% and 20%). These findings are consistent with previous
reports that (-)-THP induces volitional alcohol intake comparable to (±)-THP [53].
Alternative to the hypothesis that morphine is synthesized from the alkaloid, THP
may act as an opiate agonist. Because of the relative symmetry of the molecule,
receptors may be unable to distinguish between the two isomers. In either case, one
might expect both enantiomers would exhibit efficacy equal to the racemic mixture [53].
Unfortunately, this data cannot discriminate between these two hypotheses.
Aldehydes form as a result of the enzymatic degradation of alcohol by alcohol
dehydrogenase in the liver [31]. These peripherally formed aldehydes may react with
catecholamines such as dopamine to form THP, as well as other THIQ alkaloids, shown
to induce ethanol intake. The presumption that THIQ alkaloids are relevant to the
etiology of alcoholism appears to rest on the assumption that peripherally formed THIQ
alkaloids can cross the blood-brain barrier, and exert their behavioral effects by binding
to centrally located receptors. Picomole quantities of THP have been detected in brain
tissue using high performance liquid chromatography (HPLC) coupled with
electrochemical detection following peripheral administration of either THP [153] or
alcohol [154].
The highest concentrations of THP were found at axons associated with the
mesolimbic reward system (e.g., olfactory bulb, frontal cortex, hypothalamus).
Substantial basic and clinical research findings implicate opioid modulation of this
dopamine circuit in alcohol addiction [155-157]. Given the structural similarity of THP
to morphine, the presence of THP in the mesolimbic dopamine system is noteworthy.
The discriminative stimulus effects of THP and ethanol are apparently dissimilar to those
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of opiates [158]. Therefore, the biochemical connection is not likely to be direct.
Nonetheless, once it has crossed over the blood brain barrier, THP was mostly highly
concentrated in structures [154] that contain both dopamine and opioid receptors.
The notion that ingested alcohol could conceivably lead to a buildup of THIQ
levels in the brain has been experimentally tested [159]. Peripherally administered
ethanol (2 g/kg; IP) resulted in an increase in THP and dopamine levels measured in the
extracellular space of the nucleus accumbens in alcohol-preferring (AA) and alcoholavoiding (ANA) rats. AA rats were generally less sensitive to changes in THP,
salsolinol, or dopamine than ANA rats. The increases in THP following ethanol
administration were more pronounced in the ANA rats [159].
The fact that peripheral infusion of THP did not influence alcohol consumption in
this experiment presents a dilemma for the multiple-metabolite theory. One plausible
hypothesis is that endogenously formed THP does not contribute to any significant
degree to the etiology of alcohol addiction. In this event, THP and other THIQ alkaloids
are still pharmacological tools useful for investigating neural mechanisms that regulate
alcohol ingestion. Since the necessary compounds for endogenous THP production are
also present in the mammalian brain, it is also possible that centrally formed THP plays a
role in alcohol consumption. However, the reason for the lack of response to chronic,
peripheral infusion of THP remains unknown.
The present experiments confirm previous reports of volitional alcohol
consumption following central administration of THP. Increases'in alcohol intake were
observed following administration of the racemic compound, as well as the R(+) - isomer
of THP, but only at the lower doses tested (0.65-0.66 fig/uL). To our knowledge, the
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finding that the R(+) - isomer of THP can potentiate alcohol consumption has not been
reported previously. Increased alcohol consumption in response to low doses of racemic
THP was observed mostly in the mid-range of concentrations tested (7-13%). The R(+) isomer compound induced significant alcohol intake across a mid-range of concentrations
(4-11%), but also at much higher concentrations (15 and 20%).
Furthermore, most of the ethanol was consumed within a four hour period each
day, maximizing the pharmacological effects of ingested ethanol. At present, it is still
unclear whether or not endogenous THP plays a significant role in the etiology and
maintenance of alcohol addiction. Nonetheless, the present data verify that central
administration of THP and its R(+) - isomer can significantly alter drinking behavior in
rats such that unsweetened alcohol solutions become preferred over water.
The Effect of ICV Injections of THP on Ethanol Consumption in Adult Male SpragueDawley Rats Obtainedfrom the Prattville, AL Harlan Site
A population of adult male Sprague-Dawley rats was obtained from the Harlan
site located in Prattville, AL. These animals were treated in exactly the same manner as
the experimental animals obtained from the Frederick, MD site in regards to all
experimental procedures and animal care. This population of rats already, on average,
drank large amounts of ethanol prior to any ICV injections.
This was odd, because the conventional animal research wisdom is that SpragueDawley rats are alcohol-aversive. This occurrence of untreated animals drinking
relatively large amounts of alcohol was heretofore unreported. When contacted about this
anomalous behavior, representatives from Harlan, Inc. expressed little surprise. They
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claimed that the outbred strains of laboratory rats that Harlan vends are isolated at each
individual site.
Therefore, rats from different plants could be considered, for all intents and
purposes, to be separate strains with respect to many factors. These factors include heart
disease, debilitating aging effects, growth curves, respiratory defects, and death rate. The
representative knew nothing of the potential for alcohol drinking differences, but noted
that very few labs specify which site they prefer their rats to be shipped from. Of these
few labs, even fewer conduct addiction-related research, so it was not unusual that Harlan
had no records of the propensity for these rats from the Prattville site to consume ethanol.
Only data from animals having cannulae tips within the right lateral ventricle or at
the dorsal rim of the ventricle were included in the statistical analysis. Histological 40 um
sections were made on a Microtome cryostat and stained with cresyl violet. These
sections were visually inspected on a lightfield microscope. Data from this population of
rats is shown in Figure 37.
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Figure 37: Bar Graph Depicting Total g/kg Consumption of Prattville, AL Rats
Across Entire Twelve-Day Ethanol Screening (Rats 5,11, and 1 treated with (+)THP; Rats 7, 9,10, and 12 treated with aCSF; Rats 14,15, and 16 treated with THP
racemate)

As can be seen from the Figure 37, no THP treatments resulted in elevated
ethanol consumption. In fact, the only animal to dramatically increase its ethanol
consumption was Rat 7, a control animal. Control animals, rats 7, 9, 10, and 12, drank
significantly more ethanol over the course of the experiment than treated animals. While
rats treated with (+)-THP, rats 1,5, and 11, drank approximately the same amount of
ethanol as other tested Sprague-Dawley rats from Frederick, MD, THP treatments

resulted in a decrease in alcohol preference. Rats 14-16 drank elevated levels of ethanol
before treatment and decreased their drinking with subsequent treatment of THP
racemate.
Presently, there is no satisfactory explanation for the behavior observed from
these Prattville, AL rats. These rats may already have elevated levels of THP present in
their brain. Raising the endogenous levels of THP through ICV injections may result in
an aversive dose, as other researchers have observed in previous dose-response curve
studies of THP [56, 142]. Alternately, the Prattville, AL Harlan plant may have
unknowingly bred their rats selectively for a high ethanol preference, as Myers and coworkers have with their HEP rats [97, 160, 161].
The Effects of ICV Injections ofTHB on the Ethanol Preference of Adult Male SpragueDawley Rats Obtained from Harlan's Frederick, MD Site
Only data from animals having cannulae tips within the right lateral ventricle or at
the dorsal rim of the ventricle were included in the statistical analysis. Histological 40 urn
sections were made on a Microtome cryostat and stained with cresyl violet. These
sections were visually inspected on a lightfield microscope.
These experimental subjects were treated in the exact same manner as previous
animals with regard to animal care, surgical, injection and cannulae placement
verification procedures. The only notable difference in the treatment of these animals was
in the identity of the tested compound. These animals were given ICV injections in the
amount of 20 nmoles/day of THB. Data from this experimental group appears as Figure
38.
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Figure 38: Graph of Control and Experimental Groups of ICV THB-Treated Rats

As can be seen in the graph, no significant increases are observed when the whole
population of rats is examined. However, the large standard deviations are the result of
three subjects' dramatic increases in ethanol consumption.
As THB is not a precursor to biological opiate alkaloids [162], it is unlikely in the
extreme that opiate biosynthesis plays any part in these observed results. Also, since
THB, compared to THP, has a relatively low affinity for opioid receptors [163, 164], it is
unlikely that this very limited success is due to THB acting as an opioid agonist. Rather,
it is probably due to the action of THB on dopaminergic receptors, for which it has a
relatively high affinity [164].
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Effects of Ethanol Consumption on Tetrahydropapaveroline Levels in the Cerebrospinal
Fluid of Adult Male Sprague-Dawley Rats In Vivo
Microdialysis Recovery Determination
The amperometric electrochemical detector used in this series of experiments was
calibrated by injecting various concentrations of THP Hydrobromide in artificial CSF
(aCSF) onto the Cig ODS column used for future dialysate analyses and plotting the
detector response as a function of peak area counts. This detector response is given in
Figure 39.
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Figure 39: Detector Response of Amperometric Detector to THP
Hydrobromide
Flow rates of 0.5, 1.0, and 1.5 (j,L/minute were examined to determine the optimal
flow rate for an in vivo microdialysis experiment. Since a calibration curve had been
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established for the detector, determining the percentage of recovered from the dialysis of
the 0.69 uM "parent" solution was a simple matter of measuring the concentration of the
dialysate and expressing its concentration as a percentage of the "parent". Results from
the flow rate experiment are seen as Figure 40.

Figure 40: Percent Recovery of THP Hydrobromide in Dialysate Solution at Three
Flow Rates as Measured by HPLC-ECD

From this flow rate calibration, it can be seen that the optimal flow rate at which
to operate a CMA/11 microdialysis probe for maximum recovery of THP Hydrobromide
and repeatability is 1.0 uL/minute. This flow rate was used throughout the in vivo
microdialysis experiment.
In Vivo Microdialysis Results
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Exposure to ethanol prior to collection of dialysate definitely increased
endogenous THP levels when compared to basal levels. Representative chromatograms
of analyzed dialysates appear as Figures 41 and 42. The circled peaks in Figures 41 and
42 have retention times identical to those of prepared THP standards.

Figure 41: Representative Chromatogram of Dialysate from Rat M2 Before Ethanol
Exposure
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Figure 42: Representative Chromatogram of Dialysate from Rat M2 After Ethanol
Exposure

The data from the in vivo microdialysis on the three experimental subjects appears
as Figures 43-46. Amounts of THP in the dialysis solution were calculated using the
detector response curve displayed as Figure 39. Application of the CMA/11 probe
recoveries displayed in Figure 40 allows for the estimation of the concentration of THP in
vivo within the lateral ventricles of the experimental subjects shown in Figures 47-49.
This experiment was originally intended to be a larger study with seven experimental
subjects, but three rats damaged their implants prior to final THP level assessment. One
set of data was lost due to a loss of communication between the electrochemical detector
and the HP 3 3 96A integrator.
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Figure 43: Bar Graph showing Elevated Levels of Dialysis THP (Rat Ml) After
Exposure to Ethanol
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Figure 44: Bar Graph showing Elevated Levels of Dialysis THP (Rat M2) After
Exposure to Ethanol
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Figure 45: Bar Graph showing Elevated Levels of Dialysis THP (Rat M7) After
Exposure to Ethanol
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Figure 46: Composite Bar Graph showing Elevated Levels of Dialysis THP of All
Rats After Exposure to Ethanol
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Figure 47: Bar Graph showing Calculated In Vivo THP Concentration of the
Lateral Ventricle (Rat Ml)

Q.

x

CO

o
o

1400
1300
1200
1100
1000
900
800
700 4
600
500 i
400
300
200
100
0

• prior to ethanol
H after ethanol

-f

i £

i
2

3

i

i

±
4

Dialysis Period

Figure 48: Bar Graph showing Calculated In Vivo THP Concentration of the
Lateral Ventricle (Rat M2)
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Figure 49: Bar Graph showing Calculated In Vivo THP Concentration of the
Lateral Ventricle (Rat M7)

General Discussion of the Relevance of Results
Chiral HPLC columns for the separation of enantiomeric mixtures employing
chiral stationary phases are quite expensive, have delicate bonded phases, and are well
documented [116, 128, 165-168]. A desirable alternative to these columns would be a
cheap and effective method of creating a chiral environment that aids in the separation of
these stereoisomers. S-[3-CD is just such a compound. It vastly improves resolution of
catecholamines compared to unsubstituted cyclodextrins [129, 130].
While several researchers have conducted studies of cyclized macromolecules or
ion-pairing agents in HPLC mobile phase additives [115, 117, 129-131, 169,170], no
published studies have used subambient temperatures to enhance the thermodynamics of

86
separations. The separation of carboxylated salsolinol derivatives using chiral mobile
phase additives is difficult, at best. However, subambient temperatures coupled with the
chiral mobile phase additive S-[3-CD allow meager resolution of even these traditionally
inseparable enantiomers.
Chiral recognition is an important function for biological systems. Just as only
one stereoisomer of glucose is important for terran biosystems, only one isomer of
morphine, the S-isomer, has analgesic effects. Likewise, it was previously thought that
only one isomer of THP was effective at eliciting an alcohol-drinking response in
aversive animals. Only the S-isomer was singled out for further study by Myers and coworkers [58] or Duncan and Deitrich [56]. Sango et al. found only the S-isomer of THP
to be present in the brains of rats exposed to ethanol [51]. Tabakoff et al. found S-(-)THP to be present biological fluids of human alcoholics [171]. The experiment conducted
with ICV THP injections in Sprague-Dawley rats indicate that R-(+)-THP is just as
effective at evoking alcohol-addictive responses from rats.
Whether this result is due to the conversion of R-(+)-THP to the S-isomer or the
inability of THP-reactive receptors to distinguish between the two is unclear. Also
unclear is the precise manner in which THP evokes alcohol drinking in aversive rats.
THP may be converted to morphine in vivo [52, 103, 104, 106, 107, 111, 112, 172-175],
or THP may act as an opiate agonist and bind with opioid receptors found in the brain
[146, 163, 164, 176, 177]. It was suggested by one group of researchers that THP may
have a two-pronged effect, binding with dopaminergic and opioid receptors alike [164],
depending on the conformational rotamers of THP.
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THB has very little affinity for opiate receptors, but a much larger affinity for
dopaminergic neuroreceptors [164]. Hence, it is reasonable to surmise that if THB is
successful at evoking volitional alcohol consumption in ethanol-aversive rats,
dopaminergic neurons may be more involved than receptors that are selective for opiates
in the etiology of alcoholism. However, if THB is unsuccessful at evoking volitional
alcohol drinking, the converse is most likely true. Since ICV injections of THB were
successful in inducing alcohol consumption in few experimental animals, it is likely that
the truth is more complicated than this hypothesis.
Nonetheless, one fact is undeniable. The gastric gavage of solutions relatively
high in ethanol concentration did result in a marked increase in endogenously formed
THP in experimental animals. This fact alone implicates tetrahydroisoquinolines in the
etiology of alcohol addiction and vindicates the theories of early alcohol addiction
researchers such as Davis and Walsh [28-31] and Myers [53-55, 58, 96, 139, 178, 179].
It is noteworthy that, during the microdialysis experiment, the maximum levels of
THP were detected within the first three periods of the experiment. THP levels then
appeared to drop towards basal concentrations. This increase in initial endogenous levels
of THP following alcohol exposure is startling. While one researcher has assayed THP
concentration in brain tissues following ethanol exposure [154], no other researcher to
date has published such a change in THP levels in CSF in "real time" from a freely
behaving subject [33, 159, 180-189]. While not conclusive by any means, these
experiments, both the ICV administration of THP and the dialysis of THP from CSF
following the administration of an ethanol solution, definitely lend credence to the theory
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that THP and related alkaloids play an important role in the acquisition and maintenance
of alcohol addiction.
Observation of the amounts of THP detected in the CSF through microdialysis
indicate that endogenous THP levels, both basal and elevated through ethanol
administration, in the lateral ventricle CSF are approximately four orders of magnitude
less than the demonstrated effective ICV dose of 20 nanomoles of THP per day. This
finding would appear to support earlier reports that ICV doses as low as 50 ng are
sufficient to induce elevated ethanol consumption in rats [141].
Future experiments expanding on this line of research should replicate these
experiments with much larger experimental groups from varied rat colonies and facilities.
Additionally, future experiments should explore the relationship of opiate receptor
density versus ethanol consumption elicited via ICV injection of THP. Also of interest is
the relative persistence of endogenously formed THP within the CSF of subject Ml.
Whether this is a function of relatively low metabolic rate of the disposition of THP
within this particular subject is, as yet, unclear. Future researchers should also focus on
the determination of individual neurochemical and neuroanatomical variations as
contributing factors to the etiology of alcohol addiction.
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Please limit your description to the space provided in the box below.
Ingested ethanol is metabolized, to a large extent, by liver alcohol dehydrogenase to acetaldehyde, which can condense with
dopamine to form salsolinol (SAL). Alternatively, dopaldehyde can condense with dopamine to form tetrahydropapaveroline
(THP). another isoquinoline alkaloids. Patients with alcoholic parents had lowered (R)-SAL and (S)-SAL levels compared
with family history negative alcoholics, suggesting genetic association of disturbance of SAL biosynthesis and alcoholism. In
rats, intraventrentricular injections of SAL or THP have been shown to induce long-lasting preferences for alcohol solutions
over water. However, the critical issue is not whether TIQ's can have behavioral effects, but whether endogenously formed
TlQ's are produced in sufficient amounts to exert a significant influence on volitional alcohol consumption. Only one
published report has attempted to address this issue. These results were consistent with the hypothesis that alcohol infusion
can influence central formation of TIQ's.
The proposed experiments will evaluate levels of SAL or THP from the shell and core of the nucleus accumbens using in vivo
microdialysis following oral infusion of ethanol (1.0, 1.5, 2.0 or 2.5 g ethanol/kg), delivered by gavage in a 5 mL volume.
Sprague-Dawley rats will be used. To evaluate whether voluntary versus involuntary oral administration of ethanol influences
extracellular SAL levels differentially, separate experiments will employ the 12-day "step-up" procedure in which animals are
free to select an escalating concentration of ethanol or water. Briefly, three graduated 100 mL drinking tubes, were placed in
front of each animal's cage. One tube contained deionized water. A second tube was empty, and a third contained an alcohol
solution in water that increased in ethanol concentration over the course of the 12 days. The concentration of ethanol
(Everclear) was increased each day in the following manner: 2, 3, 4, 5, 7, 9, 11, 13, 15, 20, 25, and 30% ethanol by volume.
Prior experiments in our laboratory and others have confirmed that most Sprague-Dawley rats avoid even low concentrations
of ethanol in this paradigm. However, a smaller percentage of animals will voluntarily select even high concentrations of
unsweetened ethanol (15-20%) over water. These alcohol-preferring animals can be used to evaluate the effects of voluntary
ethanol consumption on SAL levels in the nucleus accumbens. The proposed experiments will shed light on the unresolved
and controversial issue of whether endogenously formed T1Q alkaloids may be involved in the etiology and/or maintenance of
an addiction to alcohol.
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IV. JUSTIFICATION FOR USE OF ANIMALS
Type of animal (one per form)
Amphibians
Birds
Rabbits
Reptiles
Other (please specify)
Sex

</

Male

*

Female

Fish
Rats

Mice

Either or mixed

Strain/sDecieS Sprague-Dawley rats (Harlan, Indainapolis, IN)

Size or Age 60 days of age
1.

Why must you use animals in the proposed studies?
The proposed set of experiments examine the hypothesis that endogenous THP formation in the brain may be a
critical factor in the etiology of alcohol addiction. To answer this question directiy, a microdiaylsis tube is inserted
through a surgically implanted chronic, indwelling metal cannula. For obvious reasons, it is impossible to conduct
this experimental procedure in humans. An in vivo model is necessary to ascertain whether or not THP formation
occurs in the brain in sufficient quantities to influence further drinking behavior of the animal. The findings will be
important from both a theoretical and clinical point of view. From the a clinical viewpoint, it would provide a
potential target for development of new pharmacological approaches to treat alcoholism.

Was a literature search performed to ensure that there is no duplication with the work that
is being proposed?
^ Yes
No
If yes, then please provide details about the method used for the literature search (i.e.
database used) including when the search was performed and what keywords were used.
An Internet search using Pubmed was conducted in March 2003. The following keywords were used:
tetrydropapaveroline, salsolinol, microdialsysis, isoquinoline alkaloids.
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V. NUMBER OF ANIMALS TO BE USED PER YEAR
Please explain how you determined the number of animals needed to accomplish the proposed research.
For experiments in which there will be statistical analysis of data collected from the animals, please
briefly describe the type of analysis that will be performed and how that effected the number of animals
to be used per group (or per time point) for each experiment or each series of similar experiments.
Levels of THP will be assessed via microdiaiysis following either involuntary oral administration of ethanol or voluntary consumption
of ethanol. The experimental procedure for involuntary oral administration of ethanol is as follows. Levels of THP will be assessed
following oral administration of 1.0, 1.5, 2.0 or 2.5 g ethanol/kg, delivered by gavage in a 5 mL volume. Control animals will receive
an equal volume of water by gavage. Power analyses were conducted utilizing GPOWER(Faul &Erdfefder, 1992) to determine the
sample size for this experiment. Based on the power observed in previous experiment (Sallstrom et ah, 1999), a strong effect size is
expected. Current anlysis revealed that a total sample size of N = 55 ( n = 11 per group) should be sufficient to observe significant
differences between groups and achieve an anticipated power greater than 0.80.
Another N = 55 ( n = 11 per group ) animals will be used to evaluate Salsolinol following oral administration of 1.0, 1.5,2.0 or 2.5 g
ethanol/kg, delivered by gavage in a 5 mL volume or an equal volume of the vehicle. The rationale for the number of animals is the
same as for the THP experiments (above).

Write the number of animals to be used per procedure category for each year of the project in the table
below; (If you write in the number of animals for one year only, the Committee will assume that
number is adequate for the full duration of the project.) If an animal will be used for procedures of
varying categories, write the number only in the category for the maximum level of pain/distress that the
animal may experience. Please see the instruction sheet for examples of experimental use of animals
and the category applicable for that research.
Numbers of Animals
per Year
Category

Description of Procedure Category

1

Procedure will produce minimal, transient, or no
pain/distress (e.g. minor injections or collections)

2a

Nonsurgical procedures will be performed using
anesthetics, analgesics or tranqulizers to alleviate
possible pain/distress.

2b

Nonsurvival surgical procedure will be performed
using anesthetics, analgesics or tranquilizers to
alleviate possible pain/distress.

2c

Survival surgical procedures will be performed
using anesthetics, analgesics or tranquilizers to
alleviate possible pain/distress.

3

Procedures mav produce pain/distress which will not
be relived by anesthetics, analgesics, or tranquilizers,

2

1

37

37

3

36
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VI. EXPERIMENTAL PROCEDURES
In this section a technical description of the use of the animals in the proposed research to be conducted should
be given. This section can be either written in a narrative description or drawn as a flow diagram (examples are
given in the instructions that accompany this form). Either choice should include all technical details necessary
for the committee to fully understand the use of the animals in the proposed research. The type of information
that should be included is the number of animals to be used per procedure, the treatment and control groups,
duration of the proposed research, care of the animals during the proposed research, and what will be done with
the animals at the end of the research. Conciseness will be appreciated, but you may use additional pages if
necessary.
Although rats are known to be relatively resistant to infections, subacute infections resulting in behavioral and physiological changes have been
demonstrated (Bradfield et a!., 1992). The risk of postoperative infection will be minimized by adhering to aseptic surgical practices
(Cunliff-Beamer, 1993/4). Our facility and procedures have been reviewed by Tom Ricks, D.V.M. (see below). We have a lab area dedicated to
stereotaxic surgical procedures which is equipped with mounted surgical lighting. An industrial steam pressure cleaner is used to wash animal
cages / racks. Glassware is cleaned with Alconox / Liquiox. Quatricide PV brand germicide is also used for cage cleaning. Instruments, gauze
pads, and cotton tip swabs will be initially sterilized in an autoclave (121 °C for 15 min) in Johnson Science Tower. When multiple surgeries are
performed per day, instruments are washed with disinfectant and re-sterilized with a portable Hot Bead Sterilizer. Sterile surgical drapes may be
used to cover the animal and also help to prevent hypothermia. A 60-W desk lamp will also be used to warm the animal while it is anesthetized.
Lab coats and sterile gloves are worn by the surgeon. The immediate surgical area is sterilized using 70% ethyl alcohol. During surgery,
instruments will be maintained in a solution of Zephiran chloride.
Surgical Procedures: For microdialysis experiments, animals will be anesthetized with ketamine/xylazine anesthesia (25:5 mg/kg body weight;
IM). Atropine (0.3 ml of a 0.54 mg/ml) solution may also be administered if excessive secretions of the mouth and lung are present. Also, a
2-ounce rubber squeeze ball and tube will be used to aspirate mucous from the back of the tongue if breathing becomes labored. The animals head
from behind the tips of the ears to the eyes and across the skull will be shaved with an electric razor prior to the incision. Chlorhexiderm Surgical
Scrub will be used to clean the incision site. The incision will be about 2.5 cm in length and will be performed using sterile #10 scalpel.
Following the initial incision, the periosteum is scraped to either side of the skull and the membrane is then clipped with bulldog clamps. After
cleaning and drying of the skull with cotton swabs and saline, a pencil point is made at the designated coordinates. Both bregma and lambda
reference points are used to verify the appropriate site for drilling. Following the implant of the cannula for microdialysis probe, the entire area is
cleaned with Betadine or Chlorhexiderm. Dissolved silk suture (3.0) is used to sew the fascia and skin together around the area of the pedestal
holding the cannula or probe.
The implementation of the guide cannula and the microdialysis probe into the nucleus accumbens will follow procedures for which there is an
established precedent (Sallstrom et al., 1999). Under ketamine / xylazine anesthesia, a guide cannula will be implanted. Using the bregma
reference point, stereotaxic coordinates will be anterior 1.7 mm, lateral 1.3 and ventral -6.5 mm (Paxinos and Watson, 1986). The rats will be
placed individually in a macrolon cage (size 34 X 30 X 25 cm) and tethered to the swivel in a noise-insulated room with two cages present. After
three days, a CMA 10 probe (2 mm dialysis membrane) will be inserted and perfused with artificial cerebrospinal fluid (aCSF: 137 mM Na+, 1.2
mM Ca2+, 2,4 mM K+, 144.2 mM CI -, 1.2 mM Mg 2+, 0.9 mM NaH2P04.H2O and 1A mM Na2HP04.2H20; pH 7.0) at a flow rate 1.0 *i/min,
with sampling at intervals of 20 minutes for up to 200 minutes following oral gavage administration. There will be a 24 hour delay before
collection of dialysate begins in order to minimize stress associated with implantation of the intracerebral dialysis probe. The first 5 samples
determine basal levels of THP or salsolinol from CSF prior to ethanol administration.
Experimental Procedure: Levels of THP or salsolinol wiil be assessed following oral administration of ethanol. Levels of THP will be assessed
following oral administration of 1.0, 1.5, 2.0 or 2.5 g ethanol/kg, delivered by gavage in a 5 mL volume. A 5 mL oral infusion of 20% ethanol by
gavage would equate to a 2.63 g/kg dose for a typical 300 g rat. This amount has been shown to induce clear signs of intoxication (Cowen, Chen,
Jarrott & Lawrence, 1998). Animals in the control group wiil receive oral infusion of an equal volume of water. Our dose range of ethanol is
comparable to those evaluated by other investigators (Lucas & McMillan, 2002; Fadda, Mosca, Columba & Gessa, 1989).
Perfusion for Histology: After completion of the experiment, the position of the probe will be evaluated by fixing the brain in a formalin solution
by cardiac perfusion. Animals will be deeply anesthetized with an IP injection of 60 mg/kg sodium pentobarbital. A lack of response to a paw
pinch is necessary before the perfusion procedure begins. With the rat laying on its back, the paws are pinned to a dissecting tray at an angle so
that the runoff of blood, saline, or fixative can be collected in the basin. Large scissors are used to cut through the abdominal wall (with the scissor
tips pointed upward to avoid cutting organs. The incision is made about halfway between the animal's pelvic region and ribcage. A cut is made
anteriorly until the sternum is reached and then cut laterally along either border of the ribs. The body wall is then pinned back so that the
diaphragm is exposed. A cut is made along the border between the diaphragm and the ribs, exposing the heart and lungs. A cut is made on either
side of theribsas laterally as possible, forming aflapthat can be lifted up. A hemostat is attached to the sternum, the ribs are lifted anteriorly, and
the heart is exposed. The pericardium around the heart may be removed with a pair of blunt forceps, A cannula is inserted into a small incision in
the left ventricle and another incision is made in therightatrium with fine-tip forcep to drain blood (exsanguination). When the fluid leaving the
heart is clear (using about 150 ml of saline), the valve to the saline is shut off and the valve from the formalin container is opened up and 300-400
ml of formaline is slowly infused into the animal.
Bleeding Procedure: Blood alcohol level will be tested in a subset of animals treated with ethanol. Blood will be drawn by tail snip procedure in
which an incision is made on the last 1 mm of tissue. Blood is drawn into heparinized capillary tubes and transferred into aliquots for storage at
-80 degree F freezer.
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VII. ANIMAL DISPOSITION
Based on the "Report of the AVMA Panel on Euthanasia 2000" the following methods of euthanasia are
considered either acceptable or conditionally acceptable. Place a checkmark next to the procedure(s) that will
be used to euthanize any animals for this project. The animals will be euthanized by the attending veterinarian,
the animal facility supervisor, a laboratory animal technician, or a researcher who has received special
permission from the attending veterinarian and the IACUC. If the researcher is desiring special permission to
perform the euthanasia please indicate in the appropriate space below. You must provide scientific justification
(including a detailed literature search) in order to obtain approval for a method not listed below. If the species
you are working with is not listed below, please consult with the attending veterinarian for an acceptable
method prior to submission of this form.

Species
Amphibians

Acceptable Method
Barbiturates
Inhalant anesthetics
C0 2
Double pithing
IMS
MS 222
Benzocaine hydrochloride

Conditionally Acceptable Meth
Decapitation and pithing
Stunning and decapitation

Birds

Barbiturates
Inhalant anesthetics
C0 2

Cervical dislocation
Decapitation

Fish

Barbiturates
2-phenoxyethanol

Decapitation and pithing
Stunning and
decapitation/pithing

co2
TMS
MS 222
Benzocaine hydrochloride
Rabbits

Barbiturates
Inhalant anesthetics
C02

Reptiles

Barbiturates
Inhalant anesthetics

Decapitation and pithing
Stunning and decapitation

co2
Rodents

f
•

Barbiturates
Inhalant anesthetics
CO,

Decapitation
Cervical dislocation
(in mice and rats ( < 200 g))

VII. ANIMAL DISPOSITION fCONT.)
Species not listed above will need to be specified here along with the method of euthanasia to be
employed and the signature of the attending veterinarian acknowledging that this method is acceptable.
Signature of attending veterinarian

Date

Does the researcher desire permission to perform the euthanasia?
"' Yes
If yes, then please specify why you wish to perform the euthanasia yourself.

No

To ensure that the microdialysis probes are localized within the nucleus accumbens, histological sectioning and staining of brain tissue
is necessary. Cryosectioning, in turn, requires that the brain tissue be fixed using formalin solution. Thus, intracardial perfusions are
necessary for these experiments.

Will you have tissues that may be made available to other investigators with approved, active protocols?
Please note that the other investigator can have an approved, active protocol with either our institution
or another institution. If the other investigator is at another institution a copy of their approved, active
protocol will be necessary to have on file before the tissues can be released.
Yes
^ No
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VIII. FACILITIES FOR ANIMAL USE
Where will the animals be housed?
Johnson Science Tower animal facility
(rabbits must be maintained in this facility, as well as all animals involved in biohazardous
research that aren't being conducted at the Toxicology laboratory at GCRL or animals involved
in surgical procedures)
"* Owings-McQuagge animal facility
(only rodents may be maintained in this facility)
Wet lab in Walker Science Building
(only fish, reptiles, and amphibians may be maintained in this facility)
Toxicology laboratory at GCRL
Wet lab facilities at GCRL
Field (requires information to be provided in Appendix H)
other (specify)

Describe any special housing requirements that may be needed, especially if the animal will be exposed
to hazardous materials.

Will animals be maintained outside the above stated facility overnight for periods longer than twelve
hours?
Yes *' No
If yes, provide the following information:
a.
Proposed location(s) where animals will be housed?_
b.
Estimated number of animals or cages to be housed at any given times?

d.

Length of time animals will be.housed?
Reason(s) why animals must be housed outside designated animal facilities? (Note: convenience
is not adequate justification for housing outside of approved animal facilities)
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IX. ANIMAL MEDICAL EMERGENCIES
In the table below, list the names of individuals who have authority to approve animal treatment or euthanasia.
If the designated individual(s) cannot be reached, then the Animal Research Facility veterinarian will provide
supportive care or euthanatize animals suffering unrelenting pain.
Name

Work Phone Number

Emergency Phone Number

John G. McCoy

266-4617

266-5197

Julie Rich

266-5617

297-8936

X. REQUIRED APPENDICES
(This page MUST be submitted with the application)
Yes?
A. ANTIBODY PRODUCTION
Will animals be used for antibody production?
If yes, then complete and attach Appendix A.
B. NONSURGICAL PROCEDURES NOT INCLUDING ANTIBODY
PRODUCTION
Will animals be subjected to nonsurgical procedures (i.e. injections (not including those
routinely used to administer euthanasia agents), radiographs, oral treatments, etc.?
If yes, then complete and attach Appendix B.

No?

•
•

C. BREEDING COLONIES
Will pregnant animals be required or will a breeding colony be established specifically
for this project?
If yes, then complete and attach Appendix C.
D. SURGICAL PROCEDURES
Will animals be subjected to nonsurvival and/or survival surgical procedures?
If yes, then complete and attach Appendix D.

•

•
•

E. PROLONGED PHYSICAL RESTRAINT OF UNANESTHETIZED ANIMALS
Will unanesthetized animals be subjected to physical restraint for periods of longer than
one hour?
If yes, then complete and attach Appendix E.
&

•

F. PROCEDURES INVOLVING PAIN/DISTRESS WITHOUT PAIN/DISTRESS
MEDICATION
Will animals be subjected to procedures that may produce pain/distress which will not be
relieved by anaesthetics, analgesics, or tranquilizers?
If yes, then complete and attach Appendix F.

•

G. USE OF GENETICALLY MANIPULATED ANIMALS
Will genetically manipulated animals be used?
If yes, then complete and attach Appendix G.

•

H. WILD ANIMAL AND/OR FIELD RESEARCH
Will wild animals be used in this research and/or will wild animals be held in the field
while research is being conducted on them?
If yes, then complete and attach Appendix H.

*

I. SAFETY
Will living animals be exposed to any of the following: recombinant DNA, infectious
agents, toxic chemicals, flammable or explosive materials, and/or carcinogens?
If yes, then complete and attach Appendix I.

•

•

NONSURGICAL PROCEDURES NOT INCLUDING ANTIBODY PRODUCTION
Place a check by the procedures that will be used in this application.
0Oral treatments
[EJnjections (IV, SQ, IM, etc.)
DTopicai applications
•Non-surgical catheter use
•Radiographs
•intranasal administrations
I lExercise studies
•Abnormal noise levels
•Environmental 0 2 variations
•Abnormal light levels or cycles
•Blood pressure monitoring
• F o o d or fluid restrictions
•Exposure to abnormal temperature dOther (describe)

0Blood collections
•Fluid collections
•Behavioral studies
•E.K.G.
•Ocular exams
•irradiation

Will the use of paralytics be required for these procedures?

•Yes

BNo

(Paralyzing drugs must be used only while the animals are fully anesthetized/sedated. If paralytics will
be used, blood pressure and heart rate must be monitored. Describe the methods that will, be used to
monitor for possible elevations in blood pressure and heart rate to ensure that adequate levels of
anesthesia/sedation are maintained while the animals are paralyzed).

Will the use of anesthetics be required for these procedures? 0Yes
List the anesthetic agent(s) that will be used.
Route

Dose (mg/kg body wt)

Agent
ketamine/xylazine anesthesia

25:5 mg/kg body weight

IZ]No

IM

Frequency
Once prior to surgery

fOcJ^

of the appropriate animal facility supervisor and/or attending veterinarian
Briefly describe the technique to be used for the procedure(s). Include in your description the frequency
and the maximum number of procedures to be conducted per animal.
An intramuscular injection of ketamine / xylazine anesthesia (25:5 mg/kg BW) will be given prior stereotaxic surgery (one cannula
implant per animal). This anesthetic takes full effect within about 20 minutes. The surgical stage of anesthesia is characterized by
reduced muscle tone, no spontaneous movement, no reaction to painful stimuli (paw or tail pinch) and lack of eyeblink when eyelid is
touched. Respiration should be regular. Because ketamine prevents the eyelids from closing, an eye lubricant (Paralube Vet ointment)
is applied.

SURGICAL PROCEDURES
An investigator planning on performing surgical procedures must submit documented proof of formal training
with this application. The training must have occurred within the last five years. Even with documentation it
will still be necessary for all initial surgical procedures to be performed under the supervision of the attending
veterinarian or an approved substitute. The following questions should be filled out with the assistance of the
animal facility supervisor and/or the attending veterinarian. Questions 4 through 6 and 11 require the signature
of the animal facility supervisor and/or the attending veterinarian prior to submission of this application.
1.

Will nonsurvival surgical procedures be conducted for this application?
•Yes
0No

2.

Will survival surgical procedures be conducted for this application? If animals will recover from
anesthesia for any time following surgery, it must be considered as a survival procedure.
0Yes
DNo

3.

Which of the following parameters will be used to determine the pre-operative health status?
•Activity level
| [Heart rate
•General physical condition
plRespiratory rate
•Body temperature
0Body weight
•Blood chemistries
Dither (specify)

4.

Please specify when, prior to surgery, food and fluids will be withheld.
Food will be withheld the evening prior to surgery. Water will be available ad lib.

5.

Will pre-operative, medications (i.e. antibiotics, anticholinergics, tranquilizers, etc.) be used?
•Yes (list them below)
0No
Medication

Dose (mg/kg body wt)

Route

ICJ^
of the appropriate animal facility supervisor and/or attending veterinarian

Frequency
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6.

List the anesthetic agent(s) that will be used.
Agent

ketamine/xylazine anesthesia

Dose (mg/kg body wt)
25:5 mg/kg body weight

Route
IM

Frequency
one or two (40% supplemental)

Signature of the appropriate animal facility supervisor and/or attending veterinarian
7.

Will paralytic agents be used? [UYes (list them below)
0No
(Paralyzing drugs must be used only while the animals are fully anesthetized/sedated. If paralytics will
be used, blood pressure and heart rate must be monitored. Describe the methods that will be used to
monitor for possible elevations in blood pressure and heart rate to ensure that adequate levels of
anesthesia/sedation are maintained while the animals are paralyzed).

Agent

Dose (mg/kg body wt)

Route

Frequency

Signature of the appropriate animal facility supervisor and/or attending veterinarian
8.

For each surgical procedure that is to be conducted, address the following:
a.
List the site(s) that will be used for the incision(s).
The incision will be about 2.5 cm in length along the midline of the scalpfroma point between the ears and proceeding anteriorly.

b.

Describe how the surgical site(s) will be prepared.

The animals head from behind the tips of the ears to the eyes and across the skull will be shaved with an electric razor prior to the
incision. Chlorhexiderm Surgical Scrub will be used to clean the incision site. The incision will be performed using a sterile #10 scalpel.
Following the initial incision, the periosteum is scraped to either side of the skull and the membrane is then clipped with bulldog clamps.

c.

Fpr all survival procedures, describe the type(s) of closure materials that will be used (i.e. clips,
types of suture materials, etc.).

3.0 Surgical silk suture material is used.

d.

For survival procedures conducted on non-rodent mammals, list the basic suture patterns to be
used (i.e. continuous, simple interrupted, mattress, etc.) for underlying tissues and skin.

A simple interrupted suture pattern will be used. Usually one or two sutures anterior to the cement pedestal and one or two sutures
posterior to the pedestal are sufficient.

e.

Provide a brief description of the nonsurvival and/or survival surgical procedures.

After cleaning and drying of the skull with cotton swabs and saline, a small hole is drilled in the calvarium where the guide cannula is to
be lowered. Three additional half-holes are drilled in a triangular region around the cannula hole. Anchor screws are inserted to a depth
of 1 mm to provide support for the cannula pedestal. The surface of the skull is cleaned with saline and cotten swabs. A think paste of
dental acrylic (methacrylate and powder) is prepared in a watchglass. A think metal spatula is used to apply the dental acrylic to the skull
and anchor screws. Successive layers of acrylic are applied until the anchor screw heads are completely covered. Following the implant
of the guide cannula, the entire area is cleaned with Betadine or Chlorhexiderm. Silk suture (3.0) is used to sew the fascia and skin
together around the area of the pedestal holding the cannula or probe. Following surgery, animals are placed on a warming pad.

f.

If nonsurvival procedures (animals will not be allowed to regain consciousness) will be
conducted, explain how long the animals will be maintained under anesthesia prior to euthanasia.

9.

10.

Will any animal be subjected to multiple, major survival surgical procedures? [jYes
0No
If yes, answer questions a-c below.
a.
Are the surgeries related components of the project? Explain how they are related and why they
are a scientific necessity.

b.

How many surgeries in addition to the primary surgery will be conducted per animal?

c.

How long will animals be allowed to recover between surgeries?

During anesthesia what methods or parameters will be used to monitor the animal?
To prevent hypothermia, an insulated pad will be placed beneath the animal and a heating pad will be used post-surgery. Normal rectal
temperature should be 37.5 degrees C. Labored breathing in an anesthetized animal be produced by excess mucous that needs to be
cleared from the mouth. Placing the animal on a 35 degree incline (nose down) will allow fluids to drain from the respiratory tract. A 2
ounce rubber squeeze ball and rube may be used to clar mucous from the mouth. Gasping and wheezing indicates the need for aspiration.
Aspiration is accomplished by inserting a rubber tube connected to a 5 cc syringe about 3 cm into the throat. Repeated aspiration,
however, should be avoided since it only produces more mucous. A rat that feels no pain breaths deeply and regularly throughout the
surgery. Shallow or irregular breathing may indicate either that the animal is too lightly anesthetized or conversely, it may indicate an
anesthetic overdose. Pedal and corneal reflexes will be tested throughout surgery to assess level of anesthesia. Twitching and leg
movement also identify an animal that is too lightly anesthetized. A supplemental (40% of initial injection volume) dose may be
administered. If an animal is overanesthetized, the surgery should be stopped and breathing may be assisted rubber tube.

11.

Animals that will be allowed to regain consciousness following surgery must be closely monitored until
they regain the ability to control their head movement and maintain sternal recumbency. From the list
below, check the parameters that you will use to monitor the animals' recovery from anesthesia.
Ejfeody Temperature
DPalpebral Reflex
EJvIuscle Control
•Other (specify)

Qfeart Rate
0Respiratory Rate
DSwallow Reflex
ElResponse to External Stimuli
QMucous Membrane Re-fill Times D31ood Pressure
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12.

The postoperative period is considered at an end when the skin sutures are removed or the wound is
healed.
a.
How frequently will animals be monitored during this period?
Body weight, water consumption and appearance will be monitored daily. Fluids (1-cc of saline) may be given SC.

b.

Describe any anticipated, clinically significant, adverse effects that may result from the surgical
manipulation and the care that will be provided should they occur.
Signs of postsurgical distress include a hunched back, failure to groom, reduced body weight and food intake, and extreme
vocalization in response to handling. If any of these signs are observed, Dr. Ricks will be consulted. The analgesic listed
below has been recommended due to its relatively long duration of action (8-12 hours).

c.

13.

From the list below, check the parameters that will be used
postoperative pain/distress.
0Body Weight
0Appearance
0Respiratory Rate
[ZlHeart Rate
• B o d y Temperature
0Body Posture

to determine the presence of
tZJResponse to External Stimuli
0Unprovoked behavior
ClOther Clinical Signs (explain)

Will postoperative antibiotics and/or analgesics be given?
0 Y e s (list them below)
Oslo
Medication

Buprenorphine

Dose (mg/kg body wt)
0.02-0.05 mg/kg

Route
SC

Signature of the appropriate animal facility supervisor and/or attending veterinarian

Frequency
As prescribed by veterinarian

107
REFERENCES
1.

Koob, G.F., et. al, Neurocircuitry targets in ethanol reward and dependence.
Alcoholism: Clinical and Experimental Research, 1998. 22(1): p. 3-9.

2.

Eighth Special Report to United States Congress on Alcohol and Health, National
Institute of Alcohol Abuse and Alcoholism, p. 129.

3.

McGinnis, J.M. and W.H. Foege, Actual causes of death in the United States.
Jama, 1993. 270(18): p. 2207-12.

4.

The Economic Costs of Alcohol and Drug Abuse in the United States. 1992,
National Institute on Drug Abuse and National Institute on Alcohol Abuse and
Alcoholism.

5.

Sixth Special Report to United States Congress on Alcohol and Health. 1987,
National Institute of Alcohol Abuse and Alcoholism, p. 3.

6.

in Alcohol Health and Research World. 1994, National Institute of Alcohol Abuse
and Alcoholism, p. 243-245.

7.

Bosron, W.F., T. Ehrig, and T.K. Li, Genetic factors in alcohol metabolism and
alcoholism. Seminars in Liver Disease, 1993.13(2): p. 126-135.

8.

Mega, B.T., et al., On the role of monoamine oxidase-Afor the maintenance of the
volitional consumption of ethanol in two different rat models. Naunyn
Schmiedebergs Arch Pharmacol, 2002. 366(4): p. 319-26.

9.

Harris, R.A., Ethanol actions on multiple ion channels: which are important?
Alcohol Clin Exp Res, 1999. 23(10): p. 1563-70.

10.

Israel, Y., H. Kalant, and I. Laufer, Effects of ethanol on Na, K, Mg-stimulated
microsomal ATPase activity. Biochem Pharmacol, 1965. 14(12): p. 1803-14.

11.

Israel, Y., H. Kalant, and A.E. LeBlanc, Effect of lower alcohols on potassium
transport and microsomal adenosine triphosphatase activity of rat cerebral
cortex. The Journal of Biochemistry, 1966. 100: p. 27-33.

12.

Tabakoff, B., Inhibition of sodium, potassium, and magnesium activated ATPases
by acetaldehyde and "biogenic" aldehydes. Res Commun Chem Pathol
Pharmacol, 1974. 7(3): p. 621-4.

13.

Michaelis, E.K. and S.L. Myers, Calcium binding to brain synaptosomes. Effects
of chronic ethanol intake. Biochem Pharmacol, 1979. 28(13): p. 2081-7.

14.

Ross, D.H., M.A. Medina, and H.L. Cardenas, Morphine and ethanol: selective
depletion of regional brain calcium. Science, 1974.186(4158): p. 63-5.

15.

Carlson, N.R., Physiology of Behavior. 6th ed. 1998, Boston, Mass. 103-104.

16.

Marsden, CD. and J. A. Obeso, The functions of the basal ganglia and the
paradox of stereotaxic surgery in Parkinson's disease. Brain, 1994. 117 ( Pt 4): p.
877-97.

17.

Robbins, T.W. and B.J. Everitt, Neurobehavioural mechanisms of reward and
motivation. Curr Opin Neurobiol, 1996. 6(2): p. 228-36.

18.

Robbins, T.W. and B.J. Everitt, Functional studies of the central catecholamines.
Int Rev Neurobiol, 1982. 23: p. 303-65.

19.

Pescchanski, M., et al., Bilateral motor improvement and alteration ofL-dopa
effect in two patients with Parkinson's disease following intrastriatal
transplantation of fetal ventral mesencephalon. Brain, 1994. 117: p. 487-499.

20.

Wise, R.A., The role of reward pathways in the development of drug dependence.
Pharmacol Ther, 1987. 35(1-2): p. 227-63.

109
21.

Wise, R.A., et al., Self-stimulation and drug reward mechanisms. Ann N Y Acad
Sci, 1992. 654: p. 192-8.

22.

Di Chiara, G. and A. Imperato, Ethanolpreferentially stimulates dopamine
release in the nucleus accumbens of freely moving rats. Eur J Pharmacol, 1985.
115(1): p. 131-2.

23.

Di Chiara, G. and A. Imperato, Preferential stimulation of dopamine release in
the nucleus accumbens by opiates, alcohol, and barbiturates: studies with
transcerebral dialysis in freely moving rats. Ann N Y Acad Sci, 1986. 473: p.
367-81.

24.

Di Chiara, G. and A. Imperato, Drugs abused by humans preferentially increase
synaptic dopamine concentrations in the mesolimbic system of freely moving rats.
Proc Natl Acad Sci U S A , 1988. 85(14): p. 5274-8.

25.

Di Chiara, G., et al., Drugs of abuse: biochemical surrogates of specific aspects of
natural reward? Biochem Soc Symp, 1993. 59: p. 65-81.

26.

Koob, G.F. and F.E. Bloom, Cellular and molecular mechanisms of drug
dependence. Science, 1988. 242(4879): p. 715-23.

27.

Koob, G.F., et al., Alcohol, the reward system and dependence. Exs, 1994. 71: p.
103-14.

28.

Davis, V.E., et al., Alteration of endogenous catecholamine metabolism by
ethanol ingestion. Proc Soc Exp Biol Med, 1967. 125(4): p. 1140-3.

29.

Davis, V.E. and M.J. Walsh, Alcohol addiction and tetrahydropapaveroline.
Science, 1970. 169(950): p. 1105-6.

110
30.

Davis, V.E., M.J. Walsh, and Y. Yamanaka, Augmentation of alkaloid formation
from dopamine by alcohol and acetaldehyde in vitro. J Pharmacol Exp Ther,
1970. 174(3): p. 401-12.

31.

Davis, V.E. and M.J. Walsh, Alcohol, amines, and alkaloids: a possible
biochemical basis for alcohol addiction. Science, 1970. 167(920): p. 1005-7.

32.

Cohen, G. and M. Collins, Alkaloids from catecholamines in adrenal tissue:
possible role in alcoholism. Science, 1970.167(926): p. 1749-51.

33.

Turner, A.J., et al., Tetrahydropapaveroline: formation in vivo and in vitro in rat
brain. Life Sci, 1974. 14(11): p. 2247-57.

34.

Collins, M.A. and M.G. Bigdeli, Biosynthesis of tetrahydroisoquinoline alkaloids
in brain and other tissues of ethanol-intoxicated rats. Adv Exp Med Biol, 1975.
59: p. 79-91.

35.

Collins, M.A., et al., Dopamine-relatedtetrahydroisoquinolines: significant
urinary excretion by alcoholics after alcohol consumption. Science, 1979.
206(4423): p. 1184-6.

36.

Sandler, M., et al., Tetrahydroisoquinoline alkaloids: in vivo metabolites ofLdopa in man. Nature, 1973. 241(5390): p. 439-43.

37.

Naoi, M., et al., A novel enzyme enantioselectively synthesizes (R)-salsolinol, a
precursor of a dopaminergic, N-methyl-(R)-salsolinol. Neuroscience Letters,
1996. 212(3): p. 183-186.

38.

Naoi, M., et al., N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an
animal model to an early marker of Parkinson's disease. J Neural Transm Suppl,
1997. 50: p. 89-105.

Ill
39.

Church, A.C., J.L. Fuller, and B.C. Dudek, Salsolinol differentially affects mice
selectedfor sensitivity to alcohol. Psychopharmacology (Berl), 1976. 47(1): p. 4952.

40.

Clow, A., et al., The role of salsolinol in alcohol intake and withdrawal. Prog Clin
Biol Res, 1985.183: p. 101-13.

41.

Dostert, P., M. Strolin Benedetti, and G. Dordain, Dopamine-derived alkaloids in
alcoholism and in Parkinson's and Huntington's diseases. J Neural Transm, 1988.
74(2): p. 61-74.

42.

Nagatsu, T., Isoquinoline neurotoxins in the brain and Parkinson's disease.
Neurosci Res, 1997. 29(2): p. 99-111.

43.

Perrine, D.M., N-methyl-(R)-salsolinol and Parkinson's disease. Lancet, 1998.
351(9118): p. 1818.

44.

Pictet, A. and T. Spengler, Uber die bilding von isochinolin-derivataten durch
einwirkung von methylal aufphenyl-athylamin, phenyl-alanin und tryrosin.
Chemische Berichte, 1911. 44: p. 2030-2036.

45.

Schopf, G. and H. Bayerle, Zurfrage der giogenese der isochinolin-alkaloide.
Juste Liebig's Annalen der Chemie, 1934(513): p. 190-202.

46.

Collins, M.A. and M.G. Bigdeli, Tetrahydroisoquinolines in vivo. I. Rat brain
formation of salsolinol, a condensation product of dopamine and acetaldehyde,
under certain conditions during ethanol intoxication. Life Sci, 1975. 16(4): p.
585-601.

47.

Collins, M.A., Neuroamine condensations in human subjects. Adv Exp Med Biol,
1980.126: p. 87-102.

112
48.

Collins, M.A., et al., On the occurrence, assay and metabolism of simple
tetrahydroisoquinolines in mammalian tissues. Prog Clin Biol Res, 1982. 90: p.
155-66.

49.

Cederbaum, A.I., Metabolism ofethanol, acetaldehyde, and condensation
products, in The pharmacology of alcohol and alcohol dependence, H. Begleiter
and B. Kissin, Editors. 1996, Oxford University Press: New York. p. 59-109.

50.

Davis, V.E., et al., Metabolism of tetrahydroisoquinolines and related alkaloids.
Prog Clin Biol Res, 1982. 90: p. 99-111.

51.

Sango, K., et al., Enantio-selective occurrence of (S)-tetrahydropapaveroline in
human brain. Neurosci Lett, 2000. 283(3): p. 224-6.

52.

Hosztafi, S. and Z. Furst, Endogenous morphine. Pharmacol Res, 1995. 32(1-2):
p. 15-20.

53.

Myers, R.D. and C.L. Melchior, Alcohol drinking: abnormal intake caused by
tetrahydropapaveroline in brain. Science, 1977.196(4289): p. 554-6.

54.

Myers, R.D. and M.M. Oblinger, Alcohol drinking in the rat induced by acute
intra-cerebral infusion of two tetrahydroisoquinolines and a beta-carboline. Drug
Alcohol Depend, 1977. 2(5-6): p. 469-83.

55.

Myers, R.D., Tetrahydroisoquinolines in the brain: the basis of an animal model
of alcoholism. Alcohol Clin Exp Res, 1978. 2(2): p. 145-54.

56.

Duncan, C. and R.A. Deitrich, A critical evaluation oftetrahydroisoquinoline
induced ethanolpreference in rats. Pharmacol Biochem Behav, 1980. 13(2): p.
265-81.

113
57.

Huttunen, P. and R.D. Myers, Anatomical localization in hippocampus of
tetrahydro-beta-carboline-induced alcohol drinking in the rat. Alcohol, 1987.
4(3): p. 181-7.

58.

Melchior, C.L. and R.D. Myers, Preference for alcohol evoked by
tetrahydropapaveroline (THP) chronically infused in the cerebral ventricle of the
rat. Pharmacol Biochem Behav, 1977. 7(1): p. 19-35.

59.

Myers, R.D., et al., Tetrahydropapaveroline and salsolinol alter 45Ca2+ efflux
within perfused hippocampus of unrestrained rats. Neurochem Res, 1988. 13(10):
p. 989-95.

60.

Sinclair, J.D., Morphine suppresses alcohol drinking regardless of prior alcohol
access duration. Pharmacol Biochem Behav, 1974. 2(3): p. 409-12.

61.

Blum, K., et al., Morphine suppression ofethanol withdrawal in mice.
Experientia, 1976. 32(1): p. 79-82.

62.

Beaman, CM., et al., Opioids, benzodiazepines and intake ofethanol. Alcohol,
1984. 1(1): p. 39-42.

63.

Reid, L.D. and G.A. Hunter, Morphine and naloxone modulate intake ofethanol.
Alcohol, 1984.1(1): p. 33-7.

64.

Reid, L.D., et al., Opioids and intake of alcoholic beverages. NIDA Res Monogr,
1986. 75: p. 359-62.

65.

Czirr, S.A., et al., Selected opioids modify intake of sweetened ethanol solution
among female rats. Alcohol, 1987. 4(3): p. 157-60.

114
66.

Hubbell, C.L., S.A. Czirr, and L.D. Reid, Persistence and specificity of small
doses of morphine on intake of alcoholic beverages. Alcohol, 1987. 4(3): p. 14956.

67.

Reid, L.D., et al., Morphine and diprenorphine together potentiate intake of
alcoholic beverages. Alcohol, 1987. 4(3): p. 161-8.

68.

Choi, H.W., et al., Chronically administered morphine, circadian cyclicity, and
intake of an alcoholic beverage. Alcohol, 1990. 7(1): p. 7-10.

69.

Nichols, M.L., et al., Morphine increases intake of beer among rats. Alcohol,
1991. 8(4): p. 237-40.

70.

Reid, L.D., et al., Tests of opioid deficiency hypotheses of alcoholism. Alcohol,
1991. 8(4): p. 247-57.

71.

Hodge, C.W., et al., Effects of morphine on acquisition and maintenance of
ethanol and water intake patterns in rats. Alcohol, 1992. 9(5): p. 433-40.

72.

Hubbell, C.L., R.F. Mankes, and L.D. Reid, A small dose of morphine leads rats
to drink more alcohol and achieve higher blood alcohol concentrations. Alcohol
Clin Exp Res, 1993.17(5): p. 1040-3.

73.

Harris, R.A. and C.K. Erickson, Alteration of ethanol effects by opiate
antagonists. Curr Alcohol, 1979. 5: p. 17-28.

74.

Critcher, E.C., et al., Attenuation of alcohol drinking in tetrahydroisoquinolinetreatedrats by morphine and naltrexone. Pharmacol Biochem Behav, 1983.
18(2): p. 225-9.

115
75.

Piccinelli, D., G. de Feo, and G. Mazzanti, [Naloxone and naltrexone antagonism
of various central effects of morphine]. Boll Soc Ital Biol Sper, 1986. 62(10): p.
1213-20.

76.

Kotlinska, J. and R. Langwinski, Does the blockade of opioid receptors influence
the development ofethanol dependence? Alcohol Alcohol, 1987. 22(2): p. 117-9.

77.

Oster, L. and T.T. Martinez, The effect of tetrahydropapaveroline and naltrexone
on voluntary ethanol ingestion in rats. Proc West Pharmacol Soc, 1988. 31: p.
277-9.

78.

Gardell, L.R., C.L. Hubbell, and L.D. Reid, Naltrexone persistently reduces rats'
intake of a palatable alcoholic beverage. Alcohol Clin Exp Res, 1996. 20(3): p.
584-8.

79.

Myers, R.D. and M.F. Lankford, Suppression of alcohol preference in high
alcohol drinking rats: efficacy of amperozide versus naltrexone.
Neuropsychopharmacology, 1996. 14(2): p. 139-49.

80.

Reid, L.D., et al., Periodic naltrexone and propensity to take alcoholic beverage.
Alcohol Clin Exp Res, 1996. 20(8): p. 1329-34.

81.

Middaugh, L.D., et al., Naltrexone effects on ethanol reward and discrimination
in C57BL/6mice. Alcohol Clin Exp Res, 1999. 23(3): p. 456-64.

82.

Parkes, H. and J.D. Sinclair, Reduction of alcohol drinking and upregulation of
opioid receptors by oral naltrexone in AA rats. Alcohol, 2000. 21(3): p. 215-21.

83.

Sinclair, J.D., Evidence about the use of naltrexone andfor different ways of
using it in the treatment of alcoholism. Alcohol Alcohol, 2001. 36(1): p. 2-10.

116
84.

Krishnan-Sarin, S., et al., The delta opioid receptor antagonist naltrindole
attenuates both alcohol and saccharin intake in rats selectively bredfor alcohol
preference. Psychopharmacology (Berl), 1995. 120(2): p. 177-85.

85.

Honkanen, A., et al., Alcohol drinking is reduced by a mu 1- but not by a deltaopioid receptor antagonist in alcohol-preferring rats. Eur J Pharmacol, 1996.
304(1-3): p. 7-13.

86.

Hubbell, C.L., et al., Consumption ofethanol solution is potentiated by morphine
and attenuated by naloxone persistently across repeated daily administrations.
Alcohol, 1986. 3(1): p. 39-54.

87.

Koob, G.F., et al., Neurochemical substrates for opiate reinforcement. NIDA Res
Monogr, 1986. 71: p. 146-64.

88.

Pothos, E., et al., Dopamine microdialysis in the nucleus accumbens during acute
and chronic morphine, naloxone-precipitated withdrawal and clonidine
treatment. Brain Res, 1991. 566(1-2): p. 348-50.

89.

Spanagel, R., A. Herz, and T.S. Shippenberg, The effects of opioid peptides on
dopamine release in the nucleus accumbens: an in vivo microdialysis study. J
Neurochem, 1990. 55(5): p. 1734-40.

90.

Acquas, E., M. Meloni, and G. Di Chiara, Blockade of delta-opioid receptors in
the nucleus accumbens prevents ethanol-induced stimulation of dopamine release.
Eur J Pharmacol, 1993. 230(2): p. 239-41.

91.

Myers, R.D. and E.C. Critcher, Naloxone alters alcohol drinking induced in the
rat by tetrahydropapaveroline (THP) infused ICV. Pharmacol Biochem Behav,
1982.16(5): p. 827-36.

117
92.

Myers, R.D., S. Borg, and R. Mossberg, Antagonism by naltrexone of voluntary
alcohol selection in the chronically drinking macaque monkey. Alcohol, 1986.
3(6): p. 383-8.

93.

Myers, R.D. and T.H. Privette, A neuroanatomical substrate for alcohol drinking:
identification oftetrahydropapaveroline (THP)-reactive sites in the rat brain.
Brain Res Bull, 1989. 22(5): p. 899-911.

94.

Privette, T.H. and R.D. Myers, Anatomical mapping of tetrahydropapaverolinereactive sites in brain mediating suppression of alcohol drinking in the rat. Brain
Res Bull, 1989. 22(6): p. 1039-48.

95.

Duncan, C.C. and P.W. Fernando, Effects oftetrahydropapaveroline in the
nucleus accumbens and the ventral tegmental area on ethanol preference in the
rat. Alcohol, 1991. 8(2): p. 87-90.

96.

Melchior, C.L., C.W. Simpson, and R.D. Myers, Dopamine release within
forebrain sites perfused with tetrahydroisoquinolines or tryptoline in the rat.
Brain Res Bull, 1978. 3(6): p. 631-4.

97.

Myers, R.D. and D.E. Robinson, Tetrahydropapaveroline injected in the ventral
tegmental area shifts dopamine efflux differentially in the shell and core of
nucleus accumbens in high-ethanol-preferring (HEP) rats. Alcohol, 1999. 18(1):
p. 83-90.

98.

Kranzler, H.R. and B. Orok, The pharmacology of alcoholism, in Review of
Psychiatry. 1989, American Psychiatric Press: Washington, D.C.

99.

Smith, B.R. and Z. Amit, False neurotransmitters and the effects of ethanol on the
brain. AnnN Y Acad Sci, 1987. 492: p. 384-9.

118
100.

Sinclair, J.D., et al.* Relating TIQ's, opiates, and ethanol. Prog Clin Biol Res,
1982. 90: p. 365-76.

101.

Sinclair, J.D. and R.D. Myers, Cerebroventricular tetrahydropapaveroline
infusions and ethanol consumption in the rat. Subst Alcohol Actions Misuse,
1982. 3(1-2): p. 5-24.

102.

Smith, B.R., Z.W. Brown, and Z. Amit, Chronic intraventricular administration
of tetrahydroisoquinoline alkaloids: lack of effect on voluntary ethanol
consumption in the rat. Subst Alcohol Actions Misuse, 1980. 1(2): p. 209-21.

103.

Barton, D.H., et al., Investigations on the Biosynthesis of Morphine Alkaloids. J
Chem Soc, 1965. 65: p. 2423-38.

104.

Battersby, A.R., D.M. Foulkes, and R. Binks, Alkaloid Biosynthesis. 8. Use of
Optically Active Precursors for Investigations on the Biosynthesis of Morphine
Alkaloids. J Chem Soc, 1965. 33: p. 3323-32.

105.

Battersby, A.R. and G.W. Evans, Configuration ofreticuline in the opium poppy.
Tetrahedron Lett, 1965. 18: p. 1275-8.

106.

Battersby, A.R., J.A. Martin, and E. Brochmann-Hanssen, Alkaloid biosynthesis.
X. Terminal steps in the biosynthesis of the morphine alkaloids. J Chem Soc
[Perkin 1], 1967.19: p. 1785-8.

107.

Battersby, A.R., The discovery of nature's biosynthetic pathways. Experientia,
1978. 34(1): p. 1-13.

108.

Hubbell, C.L., et al., Further studies of opioids and intake of sweetened alcoholic
beverage. Alcohol, 1988. 5(2): p. 141-6.

119
109.

Hubbell, C.L., et al., Constant infusions of morphine and intakes of sweetened
ethanol solution among rats. Alcohol, 1988. 5(5): p. 409-15.

110.

Reid, L.D., Endogenous opioids and alcohol dependence: opioid alkaloids and
the propensity to drink alcoholic beverages. Alcohol, 1996. 13(1): p. 5-11.

111.

Haber, H., et al., Alcohol induces formation of morphine precursors in the
striatum of rats. Life Sci, 1997. 60(2): p. 79-89.

112.

Battersby, A.R. and T.P. Edwards, J Chem Soc, 1960: p. 1214-1221.

113.

Brossi, A., A. Focella, and S. Teitel, Alkaloids' in mammalian tissues. I.
Condensation ofL-dopa and its two mono-O-methyl ethers with formaldehyde
and acetaldehyde. Helv Chim Acta, 1972. 55(1): p. 15-21.

114.

Hahn, G. and K. Stiehl, Ber. Dtsch. Chem. Ges., 1936. 69: p. 2627-2655.

115.

Phinney, K.W., J.W. Jackson, and L.C. Sander, Chiral recognition of
functionalized cyclodextrins in capillary electrophoresis. Electrophoresis, 2002.
23(9): p. 1308-13.

116.

Stalcup, A.M. and K.H. Gahm, A sulfated cyclodextrin chiral stationary phase for
high-performance liquid chromatography. Anal Chem, 1996. 68(8): p. 1369-74.

117.

Stalcup, A.M. and K.H. Gahm, Application of sulfated cyclodextrins to chiral
separations by capillary zone electrophoresis. Anal Chem, 1996. 68(8): p. 13608.

118.

Cole, L.A. and J.G. Dorsey, Temperature dependence of retention in reversedphase liquid chromatography. 1. Stationary-phase considerations. Anal Chem,
1992. 64(13): p. 1317-23.

120
119.

Cole, L.A., J.G, Dorsey, and K.A. Dill, Temperature dependence of retention in
reversed-phase liquid chromatography. 2. Mobile-phase considerations. Anal
Chem, 1992. 64(13): p. 1324-7.

120.

Sander, L.C. and L.R. Field, Anal Chem, 1980. 52: p. 2009-2013.

121.

Cole, S.R. and J.G. Dorsey, Effect of stationary phase solvation on shape
selectivity in reversed-phase high-performance liquid chromatography. J
Chromatogr, 1993. 635(2): p. 177-86.

122.

Meyerson, L.R., et al., Stereoselective enzymatic O-methylation of
tetrahydropapaveroline and tetrahydroxyberbine alkaloids. Biochem Pharmacol,
1979. 28(11): p. 1745-52.

123.

McMurtrey, K.D., et al., Kinetics and product distribution in pictet-spengler
cyclization of tetrahydropapaveroline to tetrahydroprotoberberine alkaloids.
Journal of Organic Chemistry, 1984. 49: p. 947.

124.

Cashaw, J.L., et al., Regioselective O-methylation of tetrahydropapaveroline and
tetrahydroxyberbine in vivo in rat brain. Biochem Pharmacol, 1983. 32(21): p.
3163-9.

125.

Shamma, M., The Isoquinoline Alkaloids: Chemistry and Pharmacology. Organic
Chemistry, ed. A.T. Blomquist and H. Wasserman. Vol. 25. 1972, New York:
Academic Press.

126.

Purvis, P.L., M. Hirst, and J.C. Baskerville, Voluntary ethanol consumption in the
rat following peripheral administrations of3-carboxy-salsolinol. Subst Alcohol
Actions Misuse, 1980.1(5-6): p. 439-45.

121
127.

Paxinos, G. and C. Watson, The rat brain in stereotaxic coordinates. 2nd ed.
1998, New York: Academic Press.

128.

Deng, Y., et al., Determination of the (R)- and (S)-enantiomers of salsolinol and
N-methylsalsolinol by use of a chiral high-performance liquid chromatographic
column. J Chromatogr B Biomed Appl, 1995. 670(1): p. 47-54.

129.

Deng, Y., et al., Assay for the (R)- and (S)-enantiomers of salsolinols in biological
samples andfoods with ion-pair high-performance liquid chromatography using
beta-cyclodextrin as a chiral mobile phase additive. J Chromatogr B Biomed Sci
Appl, 1997. 689(2): p. 313-20.

130.

Deng, Y., et al., Mechanism of enantioseparation of salsolinols, endogenous
neurotoxins in human brain, with ion-pair chromatography using betacyclodextrin as a mobile phase additive. Anal Chem, 1996. 68(17): p. 2826-31.

131.

Minami, C , et al., Preparation of (R)-N-methylsalsolinol via reversed-phase
high-performance liquid chromatography using beta-cyclodextrin as a mobilephase additive. J Chromatogr B Biomed Sci Appl, 1997. 702(1-2): p. 245-8.

132.

Walhagen, A. and L.E. Edholm, Coupled-column chromatography on
immobilized protein phases for direct separation and determination of drug
enantiomers inplasma. J Chromatogr, 1989. 473(2): p. 371-9.

133.

Dorsey, J.G. and K.A. Dill, Chem. Rev., 1989. 89: p. 331-346.

134.

Wheeler, J.F., et al., Phase transitions of reversed-phase stationary phases. Cause
and effects in the mechanism of retention. J Chromatogr, 1993. 656(1-2): p. 31733.

135.

Ying, P.T., J.G. Dorsey, and K.A. Dill, Retention mechanisms ofreversed-phase
liquid chromatography: determination of solute-solvent interaction free energies.
Anal Chem, 1989. 61(22): p. 2540-6.

136.

Sadtler Spectra: 300 MHz proton nuclear magnetic resonance standards. 1991,
Philadelphia: Sadtler Research Laboratories.

137.

Ito, K., et al., [NMR spectra of1-phenethyl-, and l-styryl-1,2,3,4tetrahydroisoquinoline derivatives]. Yakugaku Zasshi, 1970. 90(9): p. 1169-72.

138.

El-Shazly, A. and M. Wink, Tetrahydroisoquinoline and beta-carboline alkaloids
from Haloxylon articulatum (Cav.) Bunge (Chenopodiaceae). Z Naturforsch [C],
2003. 58(7-8): p. 477-80.

139.

Myers, R.D. and C.L. Melchior, Differential actions on voluntary alcohol intake
of tetrahydroisoquinolines or a beta-carboline infused chronically in the ventricle
of the rat. Pharmacol Biochem Behav, 1977. 7(4): p. 381-92.

140.

Gallant, D.M. and R. Head-Dunham, Tetrahydropapaveroline and alcohol
preference. Alcohol Clin Exp Res, 1991. 15(5): p. 900.

141.

Minano, F.J., B.A. McMillen, and R.D. Myers, Interaction of
tetrahydropapaveroline with inhibition of dopa-decarboxylase by Ro 4-4602 in
brain: effects on alcohol drinking in the rat. Alcohol, 1989. 6(2): p. 133-7.

142.

Clow, A., et al., Ethanolpreference in rats: increased consumption after
intraventricular administration of tetrahydropapaveroline. Neuropharmacology,
1983. 22(4): p. 563-5.

143.

McMillen, B.A. and H.L. Williams, Volitional consumption ofethanol by fawnhooded rats: effects of alternative solutions and drug treatments. Alcohol, 1995.
12(4): p. 345-50.

144.

Lankford, M.F., et al., Drinking of high concentrations ofethanol versus
palatable fluids in alcohol-preferring (P) rats: valid animal model of alcoholism.
Alcohol, 1991. 8(4): p. 293-9.

145.

Myers, R.D. and W.L. Veale, Alterations in volitional alcohol intake produced in
rats by chronic intraventricular infusions of acetaldehyde, paraldehyde or
methanol. Arch Int Pharmacodyn Ther, 1969. 180(1): p. 100-13.

146.

Myers, R.D., Anatomical "circuitry" in the brain mediating alcohol drinking
revealed by THF'-reactive sites in the limbic system. Alcohol, 1990. 7(5): p. 44959.

147.

Myers, R.D., Tetrahydroisoquinolines and alcoholism: where are we today?
Alcohol Clin Exp Res, 1996. 20(3): p. 498-500.

148.

Myers, R.D., Experimental alcoholism: worldwide need to standardize animal
models. Alcohol, 1996. 13(2): p. 109-10.

149.

Veale, W.L. and R.D. Myers, Increased alcohol preference in rats following
repeated exposures to alcohol. Psychopharmacologia, 1969. 15(5): p. 361-72.

150.

Myers, R.D., Isoquinolines, beta-carbolines and alcohol drinking: involvement of
opioid and dopaminergic mechanisms. Experientia, 1989. 45(5): p. 436-43.

151.

Kranzler, H.R. and R.F. Anton, Implications of recent neuropsychopharmacologic
research for understanding the etiology and development of alcoholism. J Consult
Clin Psychol, 1994. 62(6): p. 1116-26.

124
152.

Meyer, R.E. and H.R. Kranzler, Alcoholism: clinical implications of recent
research. J Clin Psychiatry, 1988. 49 Suppl: p. 8-12.

153.

Cashaw, J.L. and C.A. Geraghty, Tetrahydropapaveroline and the blood-brain
barrier in rats. Alcohol, 1991. 8(4): p. 317-9.

154.

Cashaw, J.L., Tetrahydropapaveroline in brain regions of rats after acute ethanol
administration. Alcohol, 1993. 10(2): p. 133-8.

155.

Di Chiara, G., E. Acquas, and G. Tanda, Ethanol as a neurochemical surrogate of
conventional reinforcers: the dopamine-opioid link. Alcohol, 1996. 13(1): p. 13-7.

156.

Gianoulakis, C , Implications of endogenous opioids and dopamine in alcoholism:
human and basic science studies. Alcohol Alcohol Suppl, 1996. 1: p. 33-42.

157.

Gianoulakis, C , J.P. de Waele, and J. Thavundayil, Implication of the endogenous
opioid system in excessive ethanol consumption. Alcohol, 1996. 13(1): p. 19-23.

158.

Sherman, G.T. and A. Herz, Ethanol and tetrahydroisoquinoline alkaloids do not
produce narcotic discriminative stimulus effects. Psychopharmacology (Berl),
1983. 81(3): p. 224-227.

159.

Sallstrom Baum, S., et al., Effect of ethanol on (R)- and (S)-salsolinol, salsoline,
and THP in the nucleus accumbens ofAA and ANA rats. Alcohol, 1999. 18(2-3):
p. 165-9.

160.

Myers, R.D., et al., Genetics of alcoholism: rapid development of a new highethanol-preferring (HEP) strain of female and male rats. Alcohol, 1998. 16(4): p.
343-57.

125
161.

Lucas, L.A. and B.A. McMillen, Differences in brain area concentrations of
dopamine and serotonin in Myers' High Ethanol Preferring (mHEP) and outbred
rats. J Neural Transm, 2002.109(3): p. 279-92.

162.

Brossi, A., et al., Mammalian alkaloids. 8. Synthesis and biological effects of
tetrahydropapaveroline related 1-benzyltetrahydroisoquinolines. J Med Chem,
1980. 23(6): p. 648-52.

163.

Nimit, Y., et al., Neurotransmitter, opiate and benzodiazepine receptor binding of
tetrahydroisoquinolines and beta-carbolines in brain membranes. Prog Clin Biol
Res, 1982. 90: p. 311-20.

164.

Nimit, Y., et al., Interaction of catecholamine-derived alkaloids with central
neurotransmitter receptors. J Neurosci Res, 1983. 10(2): p. 175-89.

165.

Baum, S.S. and H. Rommelspacher, Determination of total dopamine, R- and Ssalsolinol in human plasma by cyclodextrin bonded-phase liquid chromatography
with electrochemical detection. J Chromatogr B Biomed Appl, 1994. 660(2): p.
235-41.

166.

Phinney, K.W., L.C. Sander, and S.A. Wise, Coupled achiral/chiral column
techniques in subcritical fluid chromatography for the separation ofchiral and
nonchiral compounds. Anal Chem, 1998. 70(11): p. 2331-5.

167.

Williams, K.L., L.C. Sander, and S.A. Wise, Comparison of liquid and
supercritical fluid chromatography for the separation of enantiomers on chiral
stationary phases. J Pharm Biomed Anal, 1997. 15(11): p. 1789-99.

126
168.

Edholm, L.E., et al., Determination of drug enantiomers in biological samples by
coupled column liquid chromatography and liquid chromatography-mass
spectrometry. J Chromatogr, 1988. 424(1): p. 61-72.

169.

Phinney, K.W. and L.C. Sander, Additive concentration effects on
enantioselective separations in supercritical fluid chromatography. Chirality,
2003. 15(4): p. 287-94.

170.

Gahm, K.H. and A.M. Stalcup, Sulfated cyclodextrins for the chiral separations
of catecholamines and related compounds in the reversed electrophoretic polarity
mode. Chirality, 1996. 8(4): p. 316-24.

171.

Tabakoff, B., et al., Characteristics of receptors and enzymes in brains of human
alcoholics. Alcohol, 1985. 2(3): p. 419-23.

172.

Dumont, R., et al., Precursors of the mammalian synthesis of morphine: (+)salutaridine and (-)-thebaine from (+)-6-demethylsalutaridine, and (-J-N-13CH3thebaine from (-)-northebaine. FEBS Lett, 1986. 206(1): p. 125-9.

173.

Gianoulakis, C , Endogenous opioids and excessive alcohol consumption. J
Psychiatry Neurosci, 1993. 18(4): p. 148-56.

174.

Gianoulakis, C , Endogenous opioids and addiction to alcohol and other drugs of
abuse. Curr Top Med Chem, 2004. 4(1): p. 39-50.

175.

Herz, A., Multiple opiate receptors and their functional significance. J Neural
Transm Suppl, 1983. 18: p. 227-33.

176.

Berger, T., et al., Ethanol and some tetrahydroisoquinolines alter the discharge of
cortical and hippocampal neurons: relationship to endogenous opioids.
Pharmacol Biochem Behav, 1982. 17(4): p. 813-21.

127
177.

Fialip, J., et al., Study of the antinociceptive effect of tetrahydro-papaveroline
derivatives. Interaction with opioids. Life Sci, 1996. 59(11): p. PL133-9.

178.

Myers, R.D. and C.L. Melchior, Alcohol drinking in the rat after destruction of
serotonergic and catecholaminergic neurons in the brain. Res Cornmun Chem
Pathol Pharmacol, 1975.10(2): p. 363-78.

179.

Myers, R.D. and F. Mora, In vivo neurochemical analysis, by push-pull perfusion,
of the mesocortical dopaminergic system of the rat during self-stimulation. Brain
Res Bull, 1977. 2(2): p. 105-12.

180.

Cashaw, J.L., et al., A methodfor determination of subpicomole concentrations of
tetrahydropapaveroline in rat brain by high-performance liquid chromatography
with electrochemical detection. Anal Biochem, 1987. 162(1): p. 274-82.

181.

McCoy, J.G., et al., A re-evaluation of the role of tetrahydropapaveroline in
ethanol consumption in rats. Brain Res Bull, 2003. 60(1-2): p. 59-65.

182.

Cashaw, J.L., et al., Effect of acute ethanol administration on brain levels of
tetrahydropapaveroline in L-dopa-treated rats. JNeurosci Res, 1987. 18(3): p.
497-503.

183.

Weiner, H., Estimation of the in vivo concentration of salsolinol and
tetrahydropapaveroline in rat brain after the administration of ethanol. Subst
Alcohol Actions Misuse, 1980.1(3): p. 317-22.

184.

Holtz, P., K. Stock, and E. Westermann, Formation of Tetrahydropapaveroline
from Dopamine in Vitro. Nature, 1964. 203: p. 656-8.

185.

Haber, H., et al., Resolution of catecholic tetrahydroisoquinoline enantiomers and
the determination ofR- and S-salsolinol in biological samples by gas

128
chromatography-mass spectrometry. J Chromatogr B Biomed Appl, 1995. 672(2):
p. 179-87.
186.

Duncan, M.W., et al., Comparison of high-performance liquid chromatography
with electrochemical detection and gas chromatography-mass fragmentography
for the assay of salsolinol, dopamine and dopamine metabolites in food and
beverage samples. J Chromatogr, 1984. 336(1): p. 199-209.

187.

Sjoquist, B., H.A. Johnson, and S. Borg, The influence of acute ethanol on the
catecholamine system in man as reflected in cerebrospinal fluid and urine. A new
condensation product, 1-carboxysalsolinol. Drug Alcohol Depend, 1985. 16(3): p.
241-9.

188.

Lorenc-Koci, E., et al., Disposition of 1,2,3,4,-tetrahydroisoquinoline in the brain
of male Wistar and Dark Agouti rats. Brain Res, 2004. 996(2): p. 168-79.

189.

Ishida, J., M. Yamaguchi, and M. Nakamura, High-performance liquid
chromatographic determination of 1,2,3,4-tetrahydroisoquinoline in rat brain
with fluorescence detection. Anal Biochem, 1991. 195(1): p. 168-71.

